{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:03:08Z","timestamp":1778774588782,"version":"3.51.4"},"reference-count":404,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-02923-6","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T22:02:28Z","timestamp":1725573748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Breaking Barriers in Alzheimer\u2019s Disease: the Role of Advanced Drug Delivery Systems"],"prefix":"10.1208","volume":"25","author":[{"given":"Devank","family":"Shekho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3266-7649","authenticated-orcid":false,"given":"Ankit","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"1","key":"2923_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/156720510790274473","volume":"7","author":"F Angelucci","year":"2010","unstructured":"Angelucci F, et al. Alzheimer\u2019s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res. 2010;7(1):15\u201320.","journal-title":"Curr Alzheimer Res"},{"issue":"s1","key":"2923_CR2","doi-asserted-by":"publisher","first-page":"S611","DOI":"10.3233\/JAD-179935","volume":"64","author":"W Gulisano","year":"2018","unstructured":"Gulisano W, et al. Role of amyloid-\u03b2 and tau proteins in Alzheimer\u2019s disease: confuting the amyloid cascade. J Alzheimers Dis. 2018;64(s1):S611\u201331.","journal-title":"J Alzheimers Dis"},{"issue":"9533","key":"2923_CR3","first-page":"387","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s Disease Lancet. 2006;368(9533):387\u2013403.","journal-title":"Alzheimer\u2019s Disease Lancet"},{"key":"2923_CR4","doi-asserted-by":"publisher","unstructured":"Gallardo G, Holtzman DM. Amyloid-\u03b2 and Tau at the crossroads of alzheimer's disease. Adv Exp Med Biol. 2019;1184:187\u2013203. https:\/\/doi.org\/10.1007\/978-981-32-9358-8_16.","DOI":"10.1007\/978-981-32-9358-8_16"},{"issue":"6","key":"2923_CR5","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41380-022-01531-9","volume":"27","author":"DW Sirkis","year":"2022","unstructured":"Sirkis DW, et al. Dissecting the clinical heterogeneity of early-onset Alzheimer\u2019s disease. Mol Psychiatry. 2022;27(6):2674\u201388.","journal-title":"Mol Psychiatry"},{"issue":"8","key":"2923_CR6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1212\/01.wnl.0000240127.89601.83","volume":"67","author":"DA Drachman","year":"2006","unstructured":"Drachman DA. Aging of the brain, entropy, and Alzheimer disease. Neurology. 2006;67(8):1340\u201352.","journal-title":"Neurology"},{"issue":"9","key":"2923_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2174\/1567205013666160314150501","volume":"13","author":"J Dorszewska","year":"2016","unstructured":"Dorszewska J, et al. Molecular basis of familial and sporadic Alzheimer\u2019s disease. Curr Alzheimer Res. 2016;13(9):952\u201363.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2923_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.neurobiolaging.2010.03.025","volume":"33","author":"RJ Guerreiro","year":"2012","unstructured":"Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer\u2019s disease: beyond APP, PSENs and APOE. Neurobiol Aging. 2012;33(3):437\u201356.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2923_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369101","volume":"24","author":"S Sadigh-Eteghad","year":"2015","unstructured":"Sadigh-Eteghad S, et al. Amyloid-beta: a crucial factor in Alzheimer\u2019s disease. Med Principles Pract. 2015;24(1):1\u201310.","journal-title":"Med Principles Pract"},{"key":"2923_CR10","doi-asserted-by":"crossref","unstructured":"Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harbor Perspect Med. 2012;2(5):a006148.","DOI":"10.1101\/cshperspect.a006148"},{"issue":"2","key":"2923_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-122140","volume":"35","author":"SG Di Santo","year":"2013","unstructured":"Di Santo SG, et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer\u2019s disease. J Alzheimers Dis. 2013;35(2):349\u201361.","journal-title":"J Alzheimers Dis"},{"key":"2923_CR12","doi-asserted-by":"publisher","unstructured":"Ravindranath V, Sundarakumar JS. Changing demography and the challenge of dementia in India. Nat Rev Neurol. 2021;17(12):747\u2013758. https:\/\/doi.org\/10.1038\/s41582-021-00565-x.","DOI":"10.1038\/s41582-021-00565-x"},{"key":"2923_CR13","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","volume":"14","author":"X Li","year":"2022","unstructured":"Li X, et al. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132019. Front Aging Neurosci. 2022;14:937486.","journal-title":"Front Aging Neurosci"},{"key":"2923_CR14","doi-asserted-by":"crossref","unstructured":"Niotis K, et al. Dementia prevention in clinical practice. In seminars in neurology.\u00a0Stuttgart: Thieme Medical Publishers, Inc.; 2022.","DOI":"10.1055\/s-0042-1759580"},{"key":"2923_CR15","doi-asserted-by":"crossref","unstructured":"Nandi A et al. Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClinicalMedicine. 2022;51:101580.","DOI":"10.1016\/j.eclinm.2022.101580"},{"issue":"2","key":"2923_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.expneurol.2009.09.013","volume":"223","author":"ACR Fonseca","year":"2010","unstructured":"Fonseca ACR, et al. Cholesterol and statins in Alzheimer\u2019s disease: current controversies. Exp Neurol. 2010;223(2):282\u201393.","journal-title":"Exp Neurol"},{"key":"2923_CR17","unstructured":"Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer disease. In: StatPearls. StatPearls Publishing, Treasure Island (FL). 2023."},{"issue":"7","key":"2923_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/polym13071051","volume":"13","author":"M Abbas","year":"2021","unstructured":"Abbas M. Potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer\u2019s patients. Polymers. 2021;13(7):1051.","journal-title":"Polymers"},{"key":"2923_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1385\/JMN:23:1-2:105","volume":"23","author":"R Vassar","year":"2004","unstructured":"Vassar R. Bace 1: the \u03b2-secretase enzyme in alzheimer\u2019s disease. J Mol Neurosci. 2004;23:105\u201313.","journal-title":"J Mol Neurosci"},{"issue":"2","key":"2923_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101\u201312.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2923_CR21","doi-asserted-by":"crossref","unstructured":"Penke B, Bog\u00e1r F, F\u00fcl\u00f6p L. \u03b2-Amyloid and the pathomechanisms of Alzheimer\u2019s disease: a comprehensive view. Molecules. 2017;22(10):1692.","DOI":"10.3390\/molecules22101692"},{"key":"2923_CR22","doi-asserted-by":"crossref","unstructured":"Kolarova M et al. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis. 2012;2012:731526.","DOI":"10.1155\/2012\/731526"},{"issue":"3","key":"2923_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1161\/01.HYP.0000258151.00728.d8","volume":"49","author":"JA Staessen","year":"2007","unstructured":"Staessen JA, Richart T, Birkenh\u00e4ger WH. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension. 2007;49(3):389\u2013400.","journal-title":"Hypertension"},{"key":"2923_CR24","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.genrep.2021.101070","volume":"23","author":"M Cheraghzadeh","year":"2021","unstructured":"Cheraghzadeh M, et al. Amyloid Beta sharply increases HMG-CoA reductase protein levels in astrocytes isolated from C57BL\/6 mice. Gene Rep. 2021;23:101070.","journal-title":"Gene Rep"},{"key":"2923_CR25","first-page":"167","volume-title":"The mevalonate pathway in Alzheimer\u2019s disease\u2014Cholesterol and non-sterol isoprenoids","author":"A Mohamed","year":"2015","unstructured":"Mohamed A, Smith K, de Chaves EP. The mevalonate pathway in Alzheimer\u2019s disease\u2014cholesterol and non-sterol isoprenoids. Alzheimer\u2019s Disease-Challenges for the Future; 2015. pp. 167\u2013222."},{"key":"2923_CR26","doi-asserted-by":"publisher","unstructured":"Kang N, Ji Z, Li Y, Gao J, Wu X, Zhang X, et al. Metabolite-derived damage-associated molecular patterns in immunological diseases. FEBS J. 2024;291(10):2051\u20132067. https:\/\/doi.org\/10.1111\/febs.16902.","DOI":"10.1111\/febs.16902"},{"key":"2923_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.freeradbiomed.2014.07.033","volume":"76","author":"EA Bordt","year":"2014","unstructured":"Bordt EA, Polster BM. NADPH oxidase-and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair? Free Radic Biol Med. 2014;76:34\u201346.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"2923_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.biopsych.2017.05.014","volume":"83","author":"AA Pimenova","year":"2018","unstructured":"Pimenova AA, Raj T, Goate AM. Untangling genetic risk for Alzheimer\u2019s disease. Biol Psychiatry. 2018;83(4):300\u201310.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"2923_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/cn300050d","volume":"3","author":"MM Gessel","year":"2012","unstructured":"Gessel MM, et al. Familial Alzheimer\u2019s disease mutations differentially alter amyloid \u03b2-protein oligomerization. ACS Chem Neurosci. 2012;3(11):909\u201318.","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"2923_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.tins.2020.10.002","volume":"43","author":"A Podle\u015bny-Drabiniok","year":"2020","unstructured":"Podle\u015bny-Drabiniok A, Marcora E, Goate AM. Microglial phagocytosis: a disease-associated process emerging from Alzheimer\u2019s disease genetics. Trends Neurosci. 2020;43(12):965\u201379.","journal-title":"Trends Neurosci"},{"key":"2923_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fnins.2019.00164","volume":"13","author":"EM Foster","year":"2019","unstructured":"Foster EM, et al. Clusterin in Alzheimer\u2019s disease: mechanisms, genetics, and lessons from other pathologies. Front NeuroSci. 2019;13:164.","journal-title":"Front NeuroSci"},{"issue":"10","key":"2923_CR32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molmed.2013.06.004","volume":"19","author":"M-S Tan","year":"2013","unstructured":"Tan M-S, Yu J-T, Tan L. Bridging integrator 1 (BIN1): form, function, and Alzheimer\u2019s disease. Trends Mol Med. 2013;19(10):594\u2013603.","journal-title":"Trends Mol Med"},{"key":"2923_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, et al. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegeneration. 2014;9:1\u201312.","journal-title":"Mol Neurodegeneration"},{"key":"2923_CR34","doi-asserted-by":"publisher","unstructured":"Lee H, Aylward AJ, Pearse RV, Hsieh YC, Augur ZM, Benoit CR, et al. Cell-type-specific regulation of APOE levels in human neurons by the Alzheimer's disease risk gene SORL1. Cell Rep. 2023;42(8):112994. https:\/\/doi.org\/10.1016\/j.celrep.2023.112994.","DOI":"10.1016\/j.celrep.2023.112994"},{"issue":"12","key":"2923_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2923_CR36","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1002\/med.21719","volume":"41","author":"K Gadhave","year":"2021","unstructured":"Gadhave K, et al. A multitude of signaling pathways associated with Alzheimer\u2019s disease and their roles in AD pathogenesis and therapy. Med Res Rev. 2021;41(5):2689\u2013745.","journal-title":"Med Res Rev"},{"issue":"10","key":"2923_CR37","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"key":"2923_CR38","doi-asserted-by":"crossref","unstructured":"Sun X, Chen W-D, Wang Y-D. \u03b2-Amyloid: the key peptide in the pathogenesis of Alzheimer\u2019s disease. Front Pharmacol. 2015;6:221.","DOI":"10.3389\/fphar.2015.00221"},{"issue":"1","key":"2923_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000100355","volume":"4","author":"VH Finder","year":"2007","unstructured":"Finder VH, Glockshuber R. Amyloid-\u03b2 aggregation. Neurodegenerative Dis. 2007;4(1):13\u201327.","journal-title":"Neurodegenerative Dis"},{"key":"2923_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.conb.2020.02.003","volume":"61","author":"DM Walsh","year":"2020","unstructured":"Walsh DM, Selkoe DJ. Amyloid \u03b2-protein and beyond: the path forward in Alzheimer\u2019s disease. Curr Opin Neurobiol. 2020;61:116\u201324.","journal-title":"Curr Opin Neurobiol"},{"issue":"11","key":"2923_CR41","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.neurobiolaging.2013.04.021","volume":"34","author":"EA Bignante","year":"2013","unstructured":"Bignante EA, et al. Amyloid \u03b2 precursor protein as a molecular target for amyloid \u03b2\u2013induced neuronal degeneration in Alzheimer\u2019s disease. Neurobiol Aging. 2013;34(11):2525\u201337.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"2923_CR42","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3390\/ijms13033038","volume":"13","author":"NE Pryor","year":"2012","unstructured":"Pryor NE, Moss MA, Hestekin CN. Unraveling the early events of amyloid-\u03b2 protein (A\u03b2) aggregation: techniques for the determination of A\u03b2 aggregate size. Int J Mol Sci. 2012;13(3):3038\u201372.","journal-title":"Int J Mol Sci"},{"key":"2923_CR43","doi-asserted-by":"publisher","first-page":"105208","DOI":"10.1016\/j.neuint.2021.105208","volume":"151","author":"K Ono","year":"2021","unstructured":"Ono K, Watanabe-Nakayama T. Aggregation and structure of amyloid \u03b2-protein. Neurochem Int. 2021;151:105208.","journal-title":"Neurochem Int"},{"key":"2923_CR44","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","volume":"163","author":"S Muralidar","year":"2020","unstructured":"Muralidar S, et al. Role of tau protein in Alzheimer\u2019s disease: the prime pathological player. Int J Biol Macromol. 2020;163:1599\u2013617.","journal-title":"Int J Biol Macromol"},{"key":"2923_CR45","first-page":"514","volume-title":"The role of tau in Alzheimer's disease and related disorders","author":"R Medeiros","year":"2011","unstructured":"Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer\u2019s disease and related disorders. Volume 17. CNS neuroscience & therapeutics; 2011. pp. 514\u201324. 5."},{"issue":"4","key":"2923_CR46","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"R Rajmohan","year":"2017","unstructured":"Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons. J Alzheimers Dis. 2017;57(4):975\u201399.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2923_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1042\/bj3230577","volume":"323","author":"ML Billingsley","year":"1997","unstructured":"Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J. 1997;323(3):577\u201391.","journal-title":"Biochem J"},{"issue":"2","key":"2923_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","volume":"85","author":"J-Z Wang","year":"2008","unstructured":"Wang J-Z, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol. 2008;85(2):148\u201375.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"2923_CR49","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/ijms15034671","volume":"15","author":"A Mietelska-Porowska","year":"2014","unstructured":"Mietelska-Porowska A, et al. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15(3):4671\u2013713.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2923_CR50","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, et al. Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci. 2022;23(21):12841.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2923_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-022-00279-0","volume":"11","author":"L Gao","year":"2022","unstructured":"Gao L, et al. Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential. Transl Neurodegener. 2022;11(1):1\u201334.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"2923_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","volume":"11","author":"L Gao","year":"2022","unstructured":"Gao L, et al. Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential. Transl Neurodegener. 2022;11(1):4.","journal-title":"Transl Neurodegener"},{"issue":"42","key":"2923_CR53","doi-asserted-by":"publisher","first-page":"23780","DOI":"10.1039\/C8RA03620A","volume":"8","author":"K Rajasekhar","year":"2018","unstructured":"Rajasekhar K, Govindaraju T. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer\u2019s disease. RSC Adv. 2018;8(42):23780\u2013804.","journal-title":"RSC Adv"},{"key":"2923_CR54","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s12035-014-8958-4","volume":"52","author":"J-H Song","year":"2015","unstructured":"Song J-H, Yu J-T, Tan L. Brain-derived neurotrophic factor in Alzheimer\u2019s disease: risk, mechanisms, and therapy. Mol Neurobiol. 2015;52:1477\u201393.","journal-title":"Mol Neurobiol"},{"key":"2923_CR55","doi-asserted-by":"crossref","unstructured":"Miranda M, et al. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363.","DOI":"10.3389\/fncel.2019.00363"},{"key":"2923_CR56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.arr.2015.04.002","volume":"23","author":"J Tower","year":"2015","unstructured":"Tower J. Programmed cell death in aging. Ageing Res Rev. 2015;23:90\u2013100.","journal-title":"Ageing Res Rev"},{"issue":"3\u20134","key":"2923_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/08977194.2020.1864347","volume":"38","author":"NA Ismail","year":"2020","unstructured":"Ismail NA, et al. A narrative review of brain-derived neurotrophic factor (BDNF) on cognitive performance in Alzheimer\u2019s disease. Growth Factors. 2020;38(3\u20134):210\u201325.","journal-title":"Growth Factors"},{"issue":"6","key":"2923_CR58","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","volume":"11","author":"S Bathina","year":"2015","unstructured":"Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Archives Med Sci. 2015;11(6):1164\u201378.","journal-title":"Archives Med Sci"},{"issue":"7","key":"2923_CR59","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jocn.2011.12.022","volume":"19","author":"F Zhang","year":"2012","unstructured":"Zhang F, et al. Roles of brain-derived neurotrophic factor\/tropomyosin-related kinase B (BDNF\/TrkB) signalling in Alzheimer\u2019s disease. J Clin Neurosci. 2012;19(7):946\u20139.","journal-title":"J Clin Neurosci"},{"issue":"16","key":"2923_CR60","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1212\/WNL.0000000000001507","volume":"84","author":"EE Benarroch","year":"2015","unstructured":"Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84(16):1693\u2013704.","journal-title":"Neurology"},{"issue":"11","key":"2923_CR61","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.3390\/ijms19113650","volume":"19","author":"T Numakawa","year":"2018","unstructured":"Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci. 2018;19(11):3650.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2923_CR62","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrn3505","volume":"14","author":"B Lu","year":"2013","unstructured":"Lu B, et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(6):401\u201316.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"2923_CR63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3233\/JAD-2011-111037","volume":"28","author":"Y-S Ho","year":"2012","unstructured":"Ho Y-S, et al. Endoplasmic reticulum stress induces tau pathology and forms a vicious cycle: implication in Alzheimer\u2019s disease pathogenesis. J Alzheimers Dis. 2012;28(4):839\u201354.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2923_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-6-41","volume":"6","author":"A Salminen","year":"2009","unstructured":"Salminen A, et al. ER stress in Alzheimer\u2019s disease: a novel neuronal trigger for inflammation and Alzheimer\u2019s pathology. J Neuroinflamm. 2009;6(1):1\u201313.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"2923_CR65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/138945013804806532","volume":"14","author":"N Ansari","year":"2013","unstructured":"Ansari N, Khodagholi F. Molecular mechanism aspect of ER stress in Alzheimer\u2019s disease: current approaches and future strategies. Curr Drug Targets. 2013;14(1):114\u201322.","journal-title":"Curr Drug Targets"},{"key":"2923_CR66","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.arr.2021.101417","volume":"70","author":"MS Uddin","year":"2021","unstructured":"Uddin MS, Yu WS, Lim LW. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer\u2019s disease. Ageing Res Rev. 2021;70:101417.","journal-title":"Ageing Res Rev"},{"issue":"9","key":"2923_CR67","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jnr.21648","volume":"86","author":"R Resende","year":"2008","unstructured":"Resende R, et al. ER stress is involved in A\u03b2-induced GSK\u20103\u03b2 activation and tau phosphorylation. J Neurosci Res. 2008;86(9):2091\u20139.","journal-title":"J Neurosci Res"},{"issue":"3","key":"2923_CR68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.cdd.4401778","volume":"13","author":"D Lindholm","year":"2006","unstructured":"Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006;13(3):385\u201392.","journal-title":"Cell Death Differ"},{"issue":"4","key":"2923_CR69","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/01.jnen.0000218445.30535.6f","volume":"65","author":"U Unterberger","year":"2006","unstructured":"Unterberger U, et al. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathology Experimental Neurol. 2006;65(4):348\u201357.","journal-title":"J Neuropathology Experimental Neurol"},{"key":"2923_CR70","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.neuint.2020.104707","volume":"135","author":"A Akhtar","year":"2020","unstructured":"Akhtar A, Sah SP. Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer\u2019s disease. Neurochem Int. 2020;135:104707.","journal-title":"Neurochem Int"},{"issue":"18","key":"2923_CR71","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.3390\/ijms22189987","volume":"22","author":"A S\u0119dzikowska","year":"2021","unstructured":"S\u0119dzikowska A, Szablewski L. Insulin and insulin resistance in Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(18):9987.","journal-title":"Int J Mol Sci"},{"key":"2923_CR72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnins.2015.00204","volume":"9","author":"G Bedse","year":"2015","unstructured":"Bedse G, et al. Aberrant insulin signaling in Alzheimer\u2019s disease: current knowledge. Front NeuroSci. 2015;9:204.","journal-title":"Front NeuroSci"},{"issue":"11","key":"2923_CR73","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.3390\/ijms19113306","volume":"19","author":"A Tumminia","year":"2018","unstructured":"Tumminia A, et al. Type 2 diabetes mellitus and Alzheimer\u2019s disease: role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018;19(11):3306.","journal-title":"Int J Mol Sci"},{"key":"2923_CR74","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nbd.2014.09.001","volume":"72","author":"KT Dineley","year":"2014","unstructured":"Dineley KT, Jahrling JB, Denner L. Insulin resistance in Alzheimer\u2019s disease. Neurobiol Dis. 2014;72:92\u2013103.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"2923_CR75","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3233\/JAD-201587","volume":"81","author":"M De la Fuente","year":"2021","unstructured":"De la Fuente M. The role of the microbiota-gut-brain axis in the health and illness condition: a focus on Alzheimer\u2019s disease. J Alzheimers Dis. 2021;81(4):1345\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"2923_CR76","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/jcm10112358","volume":"10","author":"MG Giovannini","year":"2021","unstructured":"Giovannini MG, et al. The microbiota\u2013gut\u2013brain axis and alzheimer disease. From dysbiosis to neurodegeneration: focus on the central nervous system glial cells. J Clin Med. 2021;10(11):2358.","journal-title":"J Clin Med"},{"key":"2923_CR77","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.phrs.2020.105314","volume":"164","author":"T Doifode","year":"2021","unstructured":"Doifode T, et al. The impact of the microbiota-gut-brain axis on Alzheimer\u2019s disease pathophysiology. Pharmacol Res. 2021;164:105314.","journal-title":"Pharmacol Res"},{"key":"2923_CR78","doi-asserted-by":"publisher","first-page":"118627","DOI":"10.1016\/j.lfs.2020.118627","volume":"264","author":"P Kesika","year":"2021","unstructured":"Kesika P, et al. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer\u2019s disease. Life Sci. 2021;264:118627.","journal-title":"Life Sci"},{"key":"2923_CR79","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2013.08.013","volume":"76","author":"SI Mota","year":"2014","unstructured":"Mota SI, Ferreira IL, Rego AC. Dysfunctional synapse in Alzheimer\u2019s disease\u2013A focus on NMDA receptors. Neuropharmacology. 2014;76:16\u201326.","journal-title":"Neuropharmacology"},{"issue":"4","key":"2923_CR80","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57(4):1041\u20138.","journal-title":"J Alzheimers Dis"},{"key":"2923_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnins.2019.00043","volume":"13","author":"J Liu","year":"2019","unstructured":"Liu J, et al. The role of NMDA receptors in Alzheimer\u2019s disease. Front NeuroSci. 2019;13:43.","journal-title":"Front NeuroSci"},{"key":"2923_CR82","volume-title":"Notch signaling and ageing. in GeNeDis 2014: Neurodegeneration","author":"E Polychronidou","year":"2015","unstructured":"Polychronidou E, et al. Notch signaling and ageing. In GeNeDis 2014: neurodegeneration. Springer; 2015."},{"issue":"6","key":"2923_CR83","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nn.4288","volume":"19","author":"MD Sweeney","year":"2016","unstructured":"Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771\u201383.","journal-title":"Nat Neurosci"},{"issue":"4","key":"2923_CR84","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.bbrc.2009.10.093","volume":"390","author":"H-N Woo","year":"2009","unstructured":"Woo H-N, et al. Alzheimer\u2019s disease and notch signaling. Biochem Biophys Res Commun. 2009;390(4):1093\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"2923_CR85","doi-asserted-by":"crossref","unstructured":"Kapoor A, Nation DA. Role of Notch signaling in neurovascular aging and Alzheimer\u2019s disease. In Seminars in cell & developmental biology. Amsterdam: Elsevier; 2021.","DOI":"10.1016\/j.semcdb.2020.12.011"},{"issue":"47","key":"2923_CR86","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1523\/JNEUROSCI.1700-16.2016","volume":"36","author":"J Pearson-Leary","year":"2016","unstructured":"Pearson-Leary J, McNay EC. Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory. J Neurosci. 2016;36(47):11851\u201364.","journal-title":"J Neurosci"},{"key":"2923_CR87","doi-asserted-by":"publisher","first-page":"113076","DOI":"10.1016\/j.expneurol.2019.113076","volume":"323","author":"EC McNay","year":"2020","unstructured":"McNay EC, Pearson-Leary J. GluT4: a central player in hippocampal memory and brain insulin resistance. Exp Neurol. 2020;323:113076.","journal-title":"Exp Neurol"},{"issue":"7","key":"2923_CR88","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2174\/1570159X18666201111103024","volume":"19","author":"MJ Ram\u00edrez-Exp\u00f3sito","year":"2021","unstructured":"Ram\u00edrez-Exp\u00f3sito MJ, et al. Putative involvement of endocrine disruptors in the alzheimer\u2019s disease Via the insulin-regulated Aminopeptidase\/GLUT4 pathway. Curr Neuropharmacol. 2021;19(7):939\u201356.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2923_CR89","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4331\/wjbc.v11.i3.76","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, et al. Current understanding of glucose transporter 4 expression and functional mechanisms. World J Biol Chem. 2020;11(3):76.","journal-title":"World J Biol Chem"},{"issue":"1","key":"2923_CR90","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.90306.2008","volume":"295","author":"E Karnieli","year":"2008","unstructured":"Karnieli E, Armoni M. Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology. Am J Physiology-Endocrinology Metabolism. 2008;295(1):E38\u201345.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"2","key":"2923_CR91","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/molecules23020258","volume":"23","author":"ASM Sayem","year":"2018","unstructured":"Sayem ASM, et al. Action of phytochemicals on insulin signaling pathways accelerating glucose transporter (GLUT4) protein translocation. Molecules. 2018;23(2):258.","journal-title":"Molecules"},{"key":"2923_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt265","volume":"6","author":"Y Kitagishi","year":"2014","unstructured":"Kitagishi Y, et al. Dietary regulation of PI3K\/AKT\/GSK-3\u03b2 pathway in Alzheimer\u2019s disease. Alzheimers Res Ther. 2014;6:1\u20137.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2923_CR93","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s41983-023-00751-2","volume":"59","author":"J Limantoro","year":"2023","unstructured":"Limantoro J, de Liyis BG, Sutedja JC. Akt signaling pathway: a potential therapy for Alzheimer\u2019s disease through glycogen synthase kinase 3 beta inhibition. Egypt J Neurol Psychiatry Neurosurg. 2023;59(1):147.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"1","key":"2923_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10799893.2013.848891","volume":"34","author":"H-C Huang","year":"2014","unstructured":"Huang H-C, et al. Curcumin attenuates amyloid-\u03b2-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN\/Akt\/GSK-3\u03b2 signaling pathway. J Recept Signal Transduction. 2014;34(1):26\u201337.","journal-title":"J Recept Signal Transduction"},{"key":"2923_CR95","doi-asserted-by":"crossref","unstructured":"Zhao R et al. RETRACTED: Implication of phosphatidylinositol-3 kinase\/Akt\/glycogen synthase kinase-3\u03b2 pathway in ginsenoside Rb1\u2019s attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation. Amsterdam: Elsevier;\u00a02011.","DOI":"10.1016\/j.jep.2010.11.054"},{"key":"2923_CR96","doi-asserted-by":"publisher","first-page":"115697","DOI":"10.1016\/j.taap.2021.115697","volume":"429","author":"MA Salem","year":"2021","unstructured":"Salem MA, et al. Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer\u2019s disease in mice via modulating neuroinflammation, PI3K\/Akt, Wnt\/\u03b2-catenin, AMPK\/mTOR signaling pathways. Toxicol Appl Pharmcol. 2021;429:115697.","journal-title":"Toxicol Appl Pharmcol"},{"key":"2923_CR97","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s11064-014-1321-3","volume":"39","author":"X Zhang","year":"2014","unstructured":"Zhang X, et al. Ginsenoside Rd attenuates tau protein phosphorylation via the PI3K\/AKT\/GSK-3\u03b2 pathway after transient forebrain ischemia. Neurochem Res. 2014;39:1363\u201373.","journal-title":"Neurochem Res"},{"key":"2923_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nbd.2015.03.014","volume":"84","author":"M Perluigi","year":"2015","unstructured":"Perluigi M, Di Domenico F, Butterfield DA. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis. 2015;84:39\u201349.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"2923_CR99","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960\u201376.","journal-title":"Cell"},{"key":"2923_CR100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.freeradbiomed.2021.04.025","volume":"169","author":"M Perluigi","year":"2021","unstructured":"Perluigi M, et al. mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med. 2021;169:382\u201396.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"2923_CR101","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"23","key":"2923_CR102","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1021\/bi000169p","volume":"39","author":"H Misonou","year":"2000","unstructured":"Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid \u03b2-protein (A\u03b2) in human neuroblastoma cells. Biochemistry. 2000;39(23):6951\u20139.","journal-title":"Biochemistry"},{"issue":"9","key":"2923_CR103","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/hmg\/ddl066","volume":"15","author":"M Manczak","year":"2006","unstructured":"Manczak M, et al. Mitochondria are a direct site of A\u03b2 accumulation in Alzheimer\u2019s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15(9):1437\u201349.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2923_CR104","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3390\/biomedicines11092587","volume":"11","author":"BS Sivamaruthi","year":"2023","unstructured":"Sivamaruthi BS, et al. NF-\u03baB pathway and its inhibitors: a promising Frontier in the management of Alzheimer\u2019s Disease. Biomedicines. 2023;11(9):2587.","journal-title":"Biomedicines"},{"key":"2923_CR105","doi-asserted-by":"crossref","unstructured":"Ju Hwang C et al. NF-\u03baB as a key mediator of brain inflammation in Alzheimer\u2019s disease. CNS & Neurol Dis-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2019;18(1):3\u201310.","DOI":"10.2174\/1871527316666170807130011"},{"issue":"7","key":"2923_CR106","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1460-9568.2006.04722.x","volume":"23","author":"A Valerio","year":"2006","unstructured":"Valerio A, et al. NF-\u03baB pathway: a target for preventing \u03b2\u2010amyloid (A\u03b2)\u2010induced neuronal damage and A\u03b242 production. Eur J Neurosci. 2006;23(7):1711\u201320.","journal-title":"Eur J Neurosci"},{"issue":"4","key":"2923_CR107","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1517\/14728222.2014.989834","volume":"19","author":"M Srinivasan","year":"2015","unstructured":"Srinivasan M, Lahiri DK. Significance of NF-\u03baB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer\u2019s disease and multiple sclerosis. Expert Opin Ther Targets. 2015;19(4):471\u201387.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2923_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-016-0088-1","volume":"11","author":"M Saresella","year":"2016","unstructured":"Saresella M, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer\u2019s disease. Mol Neurodegeneration. 2016;11(1):1\u201314.","journal-title":"Mol Neurodegeneration"},{"key":"2923_CR109","doi-asserted-by":"publisher","first-page":"570711","DOI":"10.3389\/fneur.2020.570711","volume":"11","author":"KL Hanslik","year":"2020","unstructured":"Hanslik KL, Ulland TK. The role of microglia and the Nlrp3 inflammasome in Alzheimer\u2019s disease. Front Neurol. 2020;11:570711.","journal-title":"Front Neurol"},{"issue":"12","key":"2923_CR110","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.3390\/ijms21124223","volume":"21","author":"R Fusco","year":"2020","unstructured":"Fusco R, et al. Focus on the role of NLRP3 Inflammasome in diseases. Int J Mol Sci. 2020;21(12):4223.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2923_CR111","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4103\/1673-5374.272576","volume":"15","author":"Y Duan","year":"2020","unstructured":"Duan Y, Kelley N, He Y. Role of the NLRP3 inflammasome in neurodegenerative diseases and therapeutic implications. Neural Regeneration Res. 2020;15(7):1249.","journal-title":"Neural Regeneration Res"},{"key":"2923_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-019-0525-5","volume":"12","author":"L Jia","year":"2019","unstructured":"Jia L, Pi\u00f1a-Crespo J, Li Y. Restoring Wnt\/\u03b2-catenin signaling is a promising therapeutic strategy for Alzheimer\u2019s disease. Mol Brain. 2019;12:1\u201311.","journal-title":"Mol Brain"},{"key":"2923_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-3-9","volume":"3","author":"NC Inestrosa","year":"2008","unstructured":"Inestrosa NC, Toledo EM. The role of wnt signaling in neuronal dysfunction in Alzheimer\u2019s Disease. Mol Neurodegeneration. 2008;3:1\u201313.","journal-title":"Mol Neurodegeneration"},{"issue":"10","key":"2923_CR114","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.4103\/1673-5374.238606","volume":"13","author":"C Tapia-Rojas","year":"2018","unstructured":"Tapia-Rojas C, Inestrosa NC. Loss of canonical wnt signaling is involved in the pathogenesis of Alzheimer\u2019s disease. Neural Regeneration Res. 2018;13(10):1705.","journal-title":"Neural Regeneration Res"},{"issue":"7","key":"2923_CR115","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1523\/JNEUROSCI.2459-16.2017","volume":"37","author":"H Zheng","year":"2017","unstructured":"Zheng H, et al. TREM2 promotes microglial survival by activating Wnt\/\u03b2-catenin pathway. J Neurosci. 2017;37(7):1772\u201384.","journal-title":"J Neurosci"},{"issue":"2","key":"2923_CR116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.arr.2008.11.003","volume":"8","author":"RA Boonen","year":"2009","unstructured":"Boonen RA, van Tijn P, Zivkovic D. Wnt signaling in Alzheimer\u2019s disease: up or down, that is the question. Ageing Res Rev. 2009;8(2):71\u201382.","journal-title":"Ageing Res Rev"},{"issue":"7","key":"2923_CR117","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17460441.2020.1746266","volume":"15","author":"A Serafino","year":"2020","unstructured":"Serafino A, et al. Targeting the Wnt\/\u03b2-catenin pathway in neurodegenerative diseases: recent approaches and current challenges. Expert Opin Drug Discov. 2020;15(7):803\u201322.","journal-title":"Expert Opin Drug Discov"},{"key":"2923_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-012-8173-2","volume":"14","author":"Z Cai","year":"2012","unstructured":"Cai Z, et al. Roles of AMP-activated protein kinase in Alzheimer\u2019s disease. Neuromol Med. 2012;14:1\u201314.","journal-title":"Neuromol Med"},{"issue":"1","key":"2923_CR119","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1389203720666190819142746","volume":"21","author":"L Yang","year":"2020","unstructured":"Yang L, et al. AMPK: potential therapeutic target for Alzheimer\u2019s disease. Curr Protein Pept Sci. 2020;21(1):66\u201377.","journal-title":"Curr Protein Pept Sci"},{"key":"2923_CR120","doi-asserted-by":"publisher","first-page":"113043","DOI":"10.1016\/j.bbr.2020.113043","volume":"400","author":"M Chen","year":"2021","unstructured":"Chen M, et al. AMPK: a bridge between diabetes mellitus and Alzheimer\u2019s disease. Behav Brain Res. 2021;400:113043.","journal-title":"Behav Brain Res"},{"issue":"3","key":"2923_CR121","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JAD-140564","volume":"43","author":"L-L Du","year":"2015","unstructured":"Du L-L, et al. AMPK activation ameliorates Alzheimer\u2019s disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer\u2019s disease model in rats. J Alzheimers Dis. 2015;43(3):775\u201384.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2923_CR122","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1471-4159.2011.07331.x","volume":"118","author":"A Salminen","year":"2011","unstructured":"Salminen A, et al. AMP-activated protein kinase: a potential player in Alzheimer\u2019s disease. J Neurochem. 2011;118(4):460\u201374.","journal-title":"J Neurochem"},{"issue":"1","key":"2923_CR123","doi-asserted-by":"publisher","first-page":"BSR20180902","DOI":"10.1042\/BSR20180902","volume":"39","author":"P Sun","year":"2019","unstructured":"Sun P, et al. Protective role of Dihydromyricetin in Alzheimer\u2019s disease rat model associated with activating AMPK\/SIRT1 signaling pathway. Biosci Rep. 2019;39(1):BSR20180902.","journal-title":"Biosci Rep"},{"issue":"1","key":"2923_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-5960-1-3","volume":"1","author":"SC Yates","year":"2013","unstructured":"Yates SC, et al. Dysfunction of the mTOR pathway is a risk factor for Alzheimer\u2019s disease. Acta Neuropathol Commun. 2013;1(1):1\u201315.","journal-title":"Acta Neuropathol Commun"},{"key":"2923_CR125","doi-asserted-by":"crossref","unstructured":"Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci. (Scholar edition), 2012;4:941.","DOI":"10.2741\/s310"},{"issue":"3","key":"2923_CR126","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.mrrev.2008.06.001","volume":"659","author":"M Rosner","year":"2008","unstructured":"Rosner M, et al. The mTOR pathway and its role in human genetic diseases. Mutat Research\/reviews Mutat Res. 2008;659(3):284\u201392.","journal-title":"Mutat Research\/reviews Mutat Res"},{"issue":"7","key":"2923_CR127","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/ijms20071591","volume":"20","author":"X Kou","year":"2019","unstructured":"Kou X, Chen D, Chen N. Physical activity alleviates cognitive dysfunction of Alzheimer\u2019s disease through regulating the mTOR signaling pathway. Int J Mol Sci. 2019;20(7):1591.","journal-title":"Int J Mol Sci"},{"key":"2923_CR128","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.01.004","volume":"149","author":"R Franco","year":"2017","unstructured":"Franco R, et al. Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer\u2019s disease. Prog Neurobiol. 2017;149:21\u201338.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"2923_CR129","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(11)70013-8","volume":"10","author":"DJ Bonda","year":"2011","unstructured":"Bonda DJ, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 2011;10(3):275\u20139.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2923_CR130","doi-asserted-by":"publisher","first-page":"e61560","DOI":"10.1371\/journal.pone.0061560","volume":"8","author":"R Kumar","year":"2013","unstructured":"Kumar R, et al. Sirtuin1: a promising serum protein marker for early detection of Alzheimer\u2019s disease. PLoS ONE. 2013;8(4):e61560.","journal-title":"PLoS ONE"},{"issue":"31","key":"2923_CR131","doi-asserted-by":"publisher","first-page":"21745","DOI":"10.1074\/jbc.M602909200","volume":"281","author":"W Qin","year":"2006","unstructured":"Qin W, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006;281(31):21745\u201354.","journal-title":"J Biol Chem"},{"issue":"1","key":"2923_CR132","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/NEN.0b013e3181922348","volume":"68","author":"C Julien","year":"2009","unstructured":"Julien C, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathology Experimental Neurol. 2009;68(1):48\u201358.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"11","key":"2923_CR133","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.3390\/ijms22115769","volume":"22","author":"BC Mota","year":"2021","unstructured":"Mota BC, Sastre M. The role of PGC1\u03b1 in Alzheimer\u2019s disease and therapeutic interventions. Int J Mol Sci. 2021;22(11):5769.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2923_CR134","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1471-4159.2011.07581.x","volume":"120","author":"B Sheng","year":"2012","unstructured":"Sheng B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer\u2019s disease. J Neurochem. 2012;120(3):419\u201329.","journal-title":"J Neurochem"},{"key":"2923_CR135","doi-asserted-by":"publisher","first-page":"648636","DOI":"10.3389\/fphar.2021.648636","volume":"12","author":"H-Z Long","year":"2021","unstructured":"Long H-Z, et al. PI3K\/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Pharmacol. 2021;12:648636.","journal-title":"Front Pharmacol"},{"key":"2923_CR136","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S, et al. Altered insulin signaling in Alzheimer\u2019s disease brain\u2013special emphasis on PI3K-Akt pathway. Front NeuroSci. 2019;13:629.","journal-title":"Front NeuroSci"},{"key":"2923_CR137","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jep.2015.12.020","volume":"179","author":"H Li","year":"2016","unstructured":"Li H, et al. Neuroprotective effects of ginseng protein on PI3K\/Akt signaling pathway in the hippocampus of D-galactose\/AlCl3 inducing rats model of Alzheimer\u2019s disease. J Ethnopharmacol. 2016;179:162\u20139.","journal-title":"J Ethnopharmacol"},{"issue":"6","key":"2923_CR138","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s12192-021-01231-3","volume":"26","author":"E Razani","year":"2021","unstructured":"Razani E, et al. The PI3K\/Akt signaling axis in Alzheimer\u2019s disease: a valuable target to stimulate or suppress? Cell Stress Chaperones. 2021;26(6):871\u201387.","journal-title":"Cell Stress Chaperones"},{"issue":"4","key":"2923_CR139","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jnc.13932","volume":"140","author":"A Salminen","year":"2017","unstructured":"Salminen A, Kauppinen A, Kaarniranta K. Hypoxia\/ischemia activate processing of amyloid precursor protein: impact of vascular dysfunction in the pathogenesis of Alzheimer\u2019s disease. J Neurochem. 2017;140(4):536\u201349.","journal-title":"J Neurochem"},{"key":"2923_CR140","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10571-016-0440-6","volume":"37","author":"O Iyalomhe","year":"2017","unstructured":"Iyalomhe O, et al. The role of hypoxia-inducible factor 1 in mild cognitive impairment. Cell Mol Neurobiol. 2017;37:969\u201377.","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"2923_CR141","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/npp.2017.8","volume":"42","author":"C Guo","year":"2017","unstructured":"Guo C, et al. Intranasal lactoferrin enhances \u03b1-secretase-dependent amyloid precursor protein processing via the ERK1\/2-CREB and HIF-1\u03b1 pathways in an Alzheimer\u2019s disease mouse model. Neuropsychopharmacology. 2017;42(13):2504\u201315.","journal-title":"Neuropsychopharmacology"},{"issue":"28","key":"2923_CR142","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2174\/092986711797200426","volume":"18","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, et al. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr Med Chem. 2011;18(28):4335\u201343.","journal-title":"Curr Med Chem"},{"key":"2923_CR143","doi-asserted-by":"crossref","unstructured":"Bahn G et al. NRF2\/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer\u2019s models. Proc Natl Acad Sci. 2019;116(25):12516\u201312523.","DOI":"10.1073\/pnas.1819541116"},{"key":"2923_CR144","doi-asserted-by":"publisher","first-page":"100942","DOI":"10.1016\/j.arr.2019.100942","volume":"54","author":"L Fao","year":"2019","unstructured":"Fao L, Mota SI, Rego AC. Shaping the Nrf2-ARE-related pathways in Alzheimer\u2019s and Parkinson\u2019s diseases. Ageing Res Rev. 2019;54:100942.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"2923_CR145","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/157488912803252023","volume":"7","author":"G Joshi","year":"2012","unstructured":"Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discovery (Discontinued). 2012;7(3):218\u201329.","journal-title":"Recent Pat CNS Drug Discovery (Discontinued)"},{"key":"2923_CR146","doi-asserted-by":"crossref","unstructured":"Gan L, Johnson JA. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2014;1842(8):1208\u201318.","DOI":"10.1016\/j.bbadis.2013.12.011"},{"issue":"3","key":"2923_CR147","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/ars.2008.2242","volume":"11","author":"MJ Calkins","year":"2009","unstructured":"Calkins MJ, et al. The Nrf2\/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal. 2009;11(3):497\u2013508.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2923_CR148","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1196\/annals.1427.036","volume":"1147","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, et al. The Nrf2\u2013ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008;1147(1):61\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"17","key":"2923_CR149","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.3390\/ijms22179592","volume":"22","author":"E Zgorzynska","year":"2021","unstructured":"Zgorzynska E, Dziedzic B, Walczewska A. An overview of the Nrf2\/ARE pathway and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(17):9592.","journal-title":"Int J Mol Sci"},{"key":"2923_CR150","doi-asserted-by":"publisher","first-page":"787258","DOI":"10.3389\/fncel.2021.787258","volume":"15","author":"S Saha","year":"2022","unstructured":"Saha S, et al. A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Cell Neurosci. 2022;15:787258.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"2923_CR151","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3233\/JAD-141422","volume":"43","author":"BP Lucke-Wold","year":"2015","unstructured":"Lucke-Wold BP, et al. Common mechanisms of Alzheimer\u2019s disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration. J Alzheimers Dis. 2015;43(3):711\u201324.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"2923_CR152","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1523\/JNEUROSCI.5209-10.2011","volume":"31","author":"J Hongpaisan","year":"2011","unstructured":"Hongpaisan J, Sun M-K, Alkon DL. PKC \u03b5 activation prevents synaptic loss, A\u03b2 elevation, and cognitive deficits in Alzheimer\u2019s disease transgenic mice. J Neurosci. 2011;31(2):630\u201343.","journal-title":"J Neurosci"},{"key":"2923_CR153","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-420170-5.00002-7","volume":"122","author":"M-K Sun","year":"2014","unstructured":"Sun M-K, Alkon DL. The memory kinases: roles of PKC isoforms in signal processing and memory formation. Prog Mol Biol Transl Sci. 2014;122:31\u201359.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"14","key":"2923_CR154","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1096\/fj.02-0327fje","volume":"16","author":"JL Garrido","year":"2002","unstructured":"Garrido JL, et al. Protein kinase C inhibits amyloid \u03b2-peptide neurotoxicity by acting on members of the wnt pathway. FASEB J. 2002;16(14):1982\u20134.","journal-title":"FASEB J"},{"issue":"4","key":"2923_CR155","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1755-5949.2009.00115.x","volume":"17","author":"F Caraci","year":"2011","unstructured":"Caraci F, et al. TGF-\u03b21 pathway as a new target for neuroprotection in Alzheimer\u2019s disease. CNS Neurosci Ther. 2011;17(4):237\u201349.","journal-title":"CNS Neurosci Ther"},{"issue":"17","key":"2923_CR156","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-11-3224","volume":"18","author":"AL Smith","year":"2012","unstructured":"Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-\u03b2 pathway for cancer therapy. Clin Cancer Res. 2012;18(17):4514\u201321.","journal-title":"Clin Cancer Res"},{"key":"2923_CR157","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12031-018-1219-7","volume":"67","author":"Y Hu","year":"2019","unstructured":"Hu Y, et al. TGF-\u03b21 restores hippocampal synaptic plasticity and memory in Alzheimer model via the PI3K\/Akt\/Wnt\/\u03b2-catenin signaling pathway. J Mol Neurosci. 2019;67:142\u20139.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"2923_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-016-0054-4","volume":"5","author":"C Zheng","year":"2016","unstructured":"Zheng C, Zhou X-W, Wang J-Z. The dual roles of cytokines in Alzheimer\u2019s disease: update on interleukins, TNF-\u03b1, TGF-\u03b2 and IFN-\u03b3. Transl Neurodegener. 2016;5(1):1\u201315.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"2923_CR159","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1172\/JCI27341","volume":"116","author":"I Tesseur","year":"2006","unstructured":"Tesseur I, et al. Deficiency in neuronal TGF-\u03b2 signaling promotes neurodegeneration and Alzheimer\u2019s pathology. J Clin Investig. 2006;116(11):3060\u20139.","journal-title":"J Clin Investig"},{"key":"2923_CR160","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00441-011-1230-6","volume":"347","author":"F Caraci","year":"2012","unstructured":"Caraci F, et al. Dysfunction of TGF-\u03b21 signaling in Alzheimer\u2019s disease: perspectives for neuroprotection. Cell Tissue Res. 2012;347:291\u2013301.","journal-title":"Cell Tissue Res"},{"issue":"3","key":"2923_CR161","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/156720506777632916","volume":"3","author":"T Wyss-Coray","year":"2006","unstructured":"Wyss-Coray T. TGF-\u03b2 pathway as a potential target in neurodegeneration and Alzheimer\u2019s. Curr Alzheimer Res. 2006;3(3):191\u20135.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"2923_CR162","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/ijms24010864","volume":"24","author":"M Rusek","year":"2023","unstructured":"Rusek M, et al. The role of the JAK\/STAT signaling pathway in the pathogenesis of Alzheimer\u2019s Disease: new potential treatment target. Int J Mol Sci. 2023;24(1):864.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2923_CR163","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.3390\/jcm11154431","volume":"11","author":"A Tsiogka","year":"2022","unstructured":"Tsiogka A, et al. The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review. J Clin Med. 2022;11(15):4431.","journal-title":"J Clin Med"},{"key":"2923_CR164","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"I Huang","year":"2022","unstructured":"Huang I, et al. JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260.","journal-title":"Front Immunol"},{"issue":"5","key":"2923_CR165","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cells8050425","volume":"8","author":"AJ Nevado-Holgado","year":"2019","unstructured":"Nevado-Holgado AJ, et al. Genetic and real-world clinical data, combined with empirical validation, nominate Jak-Stat signaling as a target for Alzheimer\u2019s disease therapeutic development. Cells. 2019;8(5):425.","journal-title":"Cells"},{"issue":"1","key":"2923_CR166","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","volume":"1","author":"JR Molina","year":"2006","unstructured":"Molina JR, Adjei AA. The ras\/raf\/mapk pathway. J Thorac Oncol. 2006;1(1):7\u20139.","journal-title":"J Thorac Oncol"},{"key":"2923_CR167","doi-asserted-by":"crossref","unstructured":"Kim EK, Choi E-J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2010;1802(4):396\u2013405.","DOI":"10.1016\/j.bbadis.2009.12.009"},{"key":"2923_CR168","doi-asserted-by":"publisher","unstructured":"Kirouac L, et al. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer\u2019s disease. Eneuro. 2017;4(2). https:\/\/doi.org\/10.1523\/ENEURO.0149-16.2017.","DOI":"10.1523\/ENEURO.0149-16.2017"},{"issue":"8","key":"2923_CR169","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.arcmed.2012.10.015","volume":"43","author":"V Shukla","year":"2012","unstructured":"Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer\u2019s disease. Arch Med Res. 2012;43(8):655\u201362.","journal-title":"Arch Med Res"},{"issue":"11","key":"2923_CR170","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1242\/jcs.147553","volume":"127","author":"K Shah","year":"2014","unstructured":"Shah K, Lahiri DK. Cdk5 activity in the brain\u2013multiple paths of regulation. J Cell Sci. 2014;127(11):2391\u2013400.","journal-title":"J Cell Sci"},{"issue":"2","key":"2923_CR171","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1038\/cddis.2011.2","volume":"2","author":"L Crews","year":"2011","unstructured":"Crews L, et al. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer\u2019s disease. Cell Death Dis. 2011;2(2):e120\u2013120.","journal-title":"Cell Death Dis"},{"key":"2923_CR172","doi-asserted-by":"crossref","unstructured":"Maitra S, Vincent B. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer\u2019s disease: Mechanisms and possible therapeutic interventions. Life Sci. 2022;308:120986.","DOI":"10.1016\/j.lfs.2022.120986"},{"issue":"1","key":"2923_CR173","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exger.2009.10.010","volume":"45","author":"H Hampel","year":"2010","unstructured":"Hampel H, et al. Total and phosphorylated tau protein as biological markers of Alzheimer\u2019s disease. Exp Gerontol. 2010;45(1):30\u201340.","journal-title":"Exp Gerontol"},{"key":"2923_CR174","doi-asserted-by":"crossref","unstructured":"Andreasen N, Blennow K. \u03b2-Amyloid (A\u03b2) protein in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. Peptides. 2002;23(7):1205\u20131214.","DOI":"10.1016\/S0196-9781(02)00056-6"},{"key":"2923_CR175","doi-asserted-by":"crossref","unstructured":"Sergeant N, Delacourte A, Bu\u00e9e L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2005;1739(2\u20133):179\u201397.","DOI":"10.1016\/j.bbadis.2004.06.020"},{"issue":"1","key":"2923_CR176","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/s18010308","volume":"18","author":"K Islam","year":"2018","unstructured":"Islam K, et al. Development of a label-free immunosensor for clusterin detection as an Alzheimer\u2019s biomarker. Sensors. 2018;18(1):308.","journal-title":"Sensors"},{"issue":"1\u20132","key":"2923_CR177","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.05.028","volume":"333","author":"M Yarchoan","year":"2013","unstructured":"Yarchoan M, et al. Association of plasma C-reactive protein levels with the diagnosis of Alzheimer\u2019s disease. J Neurol Sci. 2013;333(1\u20132):9\u201312.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2923_CR178","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5483\/BMBRep.2020.53.1.309","volume":"53","author":"J-C Park","year":"2020","unstructured":"Park J-C, Han S-H, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer\u2019s disease: a brief review. BMB Rep. 2020;53(1):10.","journal-title":"BMB Rep"},{"issue":"12","key":"2923_CR179","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"2923_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegeneration. 2021;16(1):1\u20137.","journal-title":"Mol Neurodegeneration"},{"issue":"3","key":"2923_CR181","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/jpm10030063","volume":"10","author":"SH Omar","year":"2020","unstructured":"Omar SH, Preddy J. Advantages and pitfalls in fluid biomarkers for diagnosis of Alzheimer\u2019s disease. J Personalized Med. 2020;10(3):63.","journal-title":"J Personalized Med"},{"key":"2923_CR182","first-page":"730","volume-title":"The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis","author":"LM Forgrave","year":"2019","unstructured":"Forgrave LM, et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Volume 11. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring,; 2019. pp. 730\u201343."},{"issue":"11","key":"2923_CR183","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19(11):951\u201362.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2923_CR184","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2015;11(1):58\u201369.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"2923_CR185","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jalz.2011.04.007","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(4):474\u201385. e4.","journal-title":"Alzheimer\u2019s Dement"},{"key":"2923_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0512-1","volume":"11","author":"Y-N Ou","year":"2019","unstructured":"Ou Y-N, et al. FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: a longitudinal study. Alzheimers Res Ther. 2019;11:1\u201311.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2923_CR187","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamapsychiatry.2014.1060","volume":"71","author":"R Lautner","year":"2014","unstructured":"Lautner R, et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry. 2014;71(10):1183\u201391.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"2923_CR188","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","volume":"14","author":"H-M Lanoisel\u00e9e","year":"2017","unstructured":"Lanoisel\u00e9e H-M, et al. PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3):e1002270.","journal-title":"PLoS Med"},{"issue":"1","key":"2923_CR189","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.exger.2009.08.002","volume":"45","author":"H Zetterberg","year":"2010","unstructured":"Zetterberg H, Blennow K, Hanse E. Amyloid \u03b2 and APP as biomarkers for Alzheimer\u2019s disease. Exp Gerontol. 2010;45(1):23\u20139.","journal-title":"Exp Gerontol"},{"key":"2923_CR190","doi-asserted-by":"publisher","first-page":"585432","DOI":"10.3389\/fnins.2020.585432","volume":"14","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. microRNA-based biomarkers in Alzheimer\u2019s disease (AD). Front NeuroSci. 2020;14:585432.","journal-title":"Front NeuroSci"},{"issue":"3","key":"2923_CR191","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1515\/CCLM.2011.084","volume":"49","author":"W Herrmann","year":"2011","unstructured":"Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med. 2011;49(3):435\u201341.","journal-title":"Clin Chem Lab Med"},{"key":"2923_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1044-1","volume":"18","author":"XQ Su","year":"2019","unstructured":"Su XQ, Wang J, Sinclair AJ. Plasmalogens and Alzheimer\u2019s disease: a review. Lipids Health Dis. 2019;18:1\u201310.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2923_CR193","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"KG Yiannopoulou","year":"2013","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2013;6(1):19\u201333.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2923_CR194","first-page":"223","volume":"15","author":"KA Wollen","year":"2010","unstructured":"Wollen KA. Alzheimer\u2019s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010;15(3):223\u201344.","journal-title":"Altern Med Rev"},{"key":"2923_CR195","doi-asserted-by":"crossref","unstructured":"Mendiola-Precoma J et al. Therapies for prevention and treatment of Alzheimer\u2019s disease. BioMed Res Int. 2016;2016:1\u201317.","DOI":"10.1155\/2016\/2589276"},{"key":"2923_CR196","doi-asserted-by":"crossref","unstructured":"Folch J et al. Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast 2016;2016:8501693.","DOI":"10.1155\/2016\/8501693"},{"issue":"2","key":"2923_CR197","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"W Danysz","year":"2012","unstructured":"Danysz W, Parsons CG. Alzheimer\u2019s disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine\u2013searching for the connections. Br J Pharmacol. 2012;167(2):324\u201352.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2923_CR198","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"CG Parsons","year":"2007","unstructured":"Parsons CG, St\u00f6ffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699\u2013723.","journal-title":"Neuropharmacology"},{"issue":"10","key":"2923_CR199","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/cns.13035","volume":"24","author":"A Adlimoghaddam","year":"2018","unstructured":"Adlimoghaddam A, et al. A review of clinical treatment considerations of donepezil in severe Alzheimer\u2019s disease. CNS Neurosci Ther. 2018;24(10):876\u201388.","journal-title":"CNS Neurosci Ther"},{"key":"2923_CR200","unstructured":"Kalola UK, Nguyen H. Galantamine 2021."},{"key":"2923_CR201","unstructured":"Kuns B, Rosani A, Varghese D. Memantine. In: StatPearls. StatPearls Publishing, Treasure Island (FL). 2023."},{"key":"2923_CR202","doi-asserted-by":"crossref","unstructured":"Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease. Drug Des Dev Ther. 2016;10:3267\u20133279.","DOI":"10.2147\/DDDT.S86463"},{"issue":"34","key":"2923_CR203","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.2174\/0929867324666170712161829","volume":"24","author":"E Zanforlin","year":"2017","unstructured":"Zanforlin E, Zagotto G, Ribaudo G. An overview of new possible treatments of Alzheimer\u2019s disease, based on natural products and semi-synthetic compounds. Curr Med Chem. 2017;24(34):3749\u201373.","journal-title":"Curr Med Chem"},{"key":"2923_CR204","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2015.01.011","volume":"46","author":"X Liu","year":"2015","unstructured":"Liu X, et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer\u2019s disease. Brain Behav Immun. 2015;46:121\u201331.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"2923_CR205","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/1028415021000033767","volume":"5","author":"A Rao","year":"2002","unstructured":"Rao A, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci. 2002;5(5):291\u2013309.","journal-title":"Nutr Neurosci"},{"issue":"5","key":"2923_CR206","first-page":"70","volume":"7","author":"DJ McKenna","year":"2001","unstructured":"McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7(5):70.","journal-title":"Altern Ther Health Med"},{"key":"2923_CR207","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuint.2017.03.019","volume":"108","author":"MM El Tabaa","year":"2017","unstructured":"El Tabaa MM, et al. Neuroprotective role of Ginkgo biloba against cognitive deficits associated with Bisphenol A exposure: an animal model study. Neurochem Int. 2017;108:199\u2013212.","journal-title":"Neurochem Int"},{"key":"2923_CR208","doi-asserted-by":"crossref","unstructured":"Chang D et al. Herbal medicine for the treatment of vascular dementia: an overview of scientific evidence. Evid Based Complementary Altern Med. 2016;2016:7293626.","DOI":"10.1155\/2016\/7293626"},{"issue":"3","key":"2923_CR209","doi-asserted-by":"publisher","first-page":"044","DOI":"10.30574\/gscbps.2022.19.3.0214","volume":"19","author":"AE Al-Snafi","year":"2022","unstructured":"Al-Snafi AE. Hypotensive and vascular activities of medicinal plants. GSC Biol Pharm Sci. 2022;19(3):044\u201363.","journal-title":"GSC Biol Pharm Sci"},{"issue":"1","key":"2923_CR210","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1570163815666180219115453","volume":"16","author":"T Farkhondeh","year":"2019","unstructured":"Farkhondeh T, Yazdi HS, Samarghandian S. The protective effects of green tea catechins in the management of neurodegenerative diseases: a review. Curr Drug Discov Technol. 2019;16(1):57\u201365.","journal-title":"Curr Drug Discov Technol"},{"key":"2923_CR211","doi-asserted-by":"crossref","unstructured":"Ifegwu NO, Agbai JU, Mbanaso EL, Njoku-Oji NN, Aligwekwe AU. Combined effect of ethanolic leaf extracts of Carica papaya and Newbouldia laevis on the histology of testes of Alloxan-induced diabetic rats. World Journal of Biology Pharmacy and Health Sciences. 2023;13(1):001\u201313.","DOI":"10.30574\/wjbphs.2023.13.1.0160"},{"key":"2923_CR212","doi-asserted-by":"crossref","unstructured":"Uritu CM et al. Medicinal plants of the family Lamiaceae in pain therapy: A review. Pain Res Manag. 2018;2018:7801543.","DOI":"10.1155\/2018\/7801543"},{"key":"2923_CR213","unstructured":"Burki S et al. GC\/MS assisted phytochemical analysis of Ajuga parviflora leaves extract along with anti-hepatotoxic effect against anti-tubercular drug induced liver toxicity in rat. Pak J Pharm Sci. 2020;33:325-331."},{"issue":"1","key":"2923_CR214","first-page":"1","volume":"3","author":"N Sultana","year":"2018","unstructured":"Sultana N. Plants of genus Rubus as a source of pharmaceuticals. CPQ Nutr. 2018;3(1):1\u201371.","journal-title":"CPQ Nutr"},{"key":"2923_CR215","doi-asserted-by":"publisher","unstructured":"Bashir MI, Aziz NHKA, Noor\u00a0DAM. Polygonum minus aqueous extract supplement reduces stress-induced anorexia and anhedonia in mice.\u00a0https:\/\/doi.org\/10.53350\/pjmhs22161696","DOI":"10.53350\/pjmhs22161696"},{"issue":"3","key":"2923_CR216","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-2008-13308","volume":"13","author":"I Boldogh","year":"2008","unstructured":"Boldogh I, Kruzel ML. Colostrinin\u2122: an oxidative stress modulator for prevention and treatment of age-related disorders. J Alzheimers Dis. 2008;13(3):303\u201321.","journal-title":"J Alzheimers Dis"},{"key":"2923_CR217","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"H Wen","year":"2015","unstructured":"Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J. 2015;17:1327\u201340.","journal-title":"AAPS J"},{"key":"2923_CR218","doi-asserted-by":"crossref","unstructured":"Kumar V. Target-oriented drug delivery systems. In Modern Pharmaceutics, vol 2.\u00a0Boca Raton: CRC Press;\u00a02016.\u00a0pp. 347\u2013416.","DOI":"10.3109\/9781420065688-13"},{"key":"2923_CR219","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee S, Glendenning P, Inderjeeth C. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22:741\u201353.","journal-title":"Osteoporos Int"},{"issue":"2","key":"2923_CR220","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms20020381","volume":"20","author":"KH Wong","year":"2019","unstructured":"Wong KH, et al. Review of current strategies for delivering Alzheimer\u2019s disease drugs across the blood-brain barrier. Int J Mol Sci. 2019;20(2):381.","journal-title":"Int J Mol Sci"},{"key":"2923_CR221","doi-asserted-by":"publisher","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491.","journal-title":"Biomaterials"},{"issue":"2","key":"2923_CR222","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/jcp.24791","volume":"230","author":"SK Das","year":"2015","unstructured":"Das SK, et al. Gene therapies for cancer: strategies, challenges and successes. J Cell Physiol. 2015;230(2):259\u201371.","journal-title":"J Cell Physiol"},{"key":"2923_CR223","doi-asserted-by":"publisher","unstructured":"Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: Ahmad I, Aqil F, Owais M, editors. Modern Phytomedicine. 2006. https:\/\/doi.org\/10.1002\/9783527609987.ch2","DOI":"10.1002\/9783527609987.ch2"},{"issue":"S1","key":"2923_CR224","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1177\/0091270006288734","volume":"46","author":"H Geerts","year":"2006","unstructured":"Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl\u2010D\u2010aspartate receptors for combination therapy in the treatment of Alzheimer\u2019s disease. J Clin Pharmacol. 2006;46(S1):S8\u201316.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2923_CR225","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14740338.2020.1721456","volume":"19","author":"A Haake","year":"2020","unstructured":"Haake A, et al. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Exp Opin Drug Saf. 2020;19(2):147\u201357.","journal-title":"Exp Opin Drug Saf"},{"key":"2923_CR226","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Morales V et al. Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer\u2019s disease. Biomedicines. 2021;9(12):1910.","DOI":"10.3390\/biomedicines9121910"},{"issue":"7","key":"2923_CR227","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1517\/17425247.2016.1162152","volume":"13","author":"YE Choonara","year":"2016","unstructured":"Choonara YE, et al. Improving drug delivery technology for treating neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13(7):1029\u201343.","journal-title":"Expert Opin Drug Deliv"},{"key":"2923_CR228","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","volume":"270","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, et al. Crossing the blood-brain barrier with nanoparticles. J Controlled Release. 2018;270:290\u2013303.","journal-title":"J Controlled Release"},{"issue":"46","key":"2923_CR229","doi-asserted-by":"publisher","first-page":"1801362","DOI":"10.1002\/adma.201801362","volume":"30","author":"D Furtado","year":"2018","unstructured":"Furtado D, et al. Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30(46):1801362.","journal-title":"Adv Mater"},{"key":"2923_CR230","doi-asserted-by":"crossref","unstructured":"Zhu X et al. Brain drug delivery by adsorption-mediated transcytosis, in Brain targeted drug delivery system. Amsterdam: Elsevier;\u00a02019. pp. 159\u2013183.","DOI":"10.1016\/B978-0-12-814001-7.00007-X"},{"issue":"4","key":"2923_CR231","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/cpb.c19-00854","volume":"68","author":"T Tashima","year":"2020","unstructured":"Tashima T. Smart strategies for therapeutic agent delivery into brain across the blood\u2013brain barrier using receptor-mediated transcytosis. Chem Pharm Bull. 2020;68(4):316\u201325.","journal-title":"Chem Pharm Bull"},{"issue":"1","key":"2923_CR232","doi-asserted-by":"publisher","first-page":"e1153568","DOI":"10.1080\/21688370.2016.1153568","volume":"4","author":"AM Grabrucker","year":"2016","unstructured":"Grabrucker AM, et al. Nanoparticle transport across the blood brain barrier. Tissue Barriers. 2016;4(1):e1153568.","journal-title":"Tissue Barriers"},{"key":"2923_CR233","doi-asserted-by":"crossref","unstructured":"Fonseca-Santos B, Gremi\u00e3o MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomed. 2015;10:4981\u20135003.","DOI":"10.2147\/IJN.S87148"},{"key":"2923_CR234","doi-asserted-by":"publisher","first-page":"122167","DOI":"10.1016\/j.ijpharm.2022.122167","volume":"626","author":"S Andrade","year":"2022","unstructured":"Andrade S, et al. Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer\u2019s disease therapy. Int J Pharm. 2022;626:122167.","journal-title":"Int J Pharm"},{"issue":"7","key":"2923_CR235","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/03639045.2010.541262","volume":"37","author":"NB Mutlu","year":"2011","unstructured":"Mutlu NB, et al. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm. 2011;37(7):775\u201389.","journal-title":"Drug Dev Ind Pharm"},{"issue":"13","key":"2923_CR236","doi-asserted-by":"publisher","first-page":"10494","DOI":"10.3390\/ijms241310494","volume":"24","author":"L Vasileva","year":"2023","unstructured":"Vasileva L, et al. Mitochondria-targeted delivery strategy of dual-loaded liposomes for Alzheimer\u2019s Disease Therapy. Int J Mol Sci. 2023;24(13):10494.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2923_CR237","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/foods11172673","volume":"11","author":"Z Kuedo","year":"2022","unstructured":"Kuedo Z, et al. Oral administration of ethanolic extract of shrimp shells-loaded Liposome protects against A\u03b2-Induced memory impairment in rats. Foods. 2022;11(17):2673.","journal-title":"Foods"},{"issue":"2","key":"2923_CR238","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"W Li","year":"2012","unstructured":"Li W, et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol. 2012;34(2):272\u20139.","journal-title":"Environ Toxicol Pharmacol"},{"key":"2923_CR239","unstructured":"Keerthana D, Kavitha R, Damodharan N. Niosome as a promising carrier targeting Alzheimer\u2019s disease across the Blood Brain Barrier. NeuroQuantology. 2022;20(9):2453."},{"key":"2923_CR240","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2021.02.015","volume":"163","author":"P Kulkarni","year":"2021","unstructured":"Kulkarni P, Rawtani D, Barot T. Design, development and in-vitro\/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease. Eur J Pharm Biopharm. 2021;163:1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"key":"2923_CR241","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ijbiomac.2019.07.003","volume":"137","author":"H Moulahoum","year":"2019","unstructured":"Moulahoum H, et al. Potential effect of carnosine encapsulated niosomes in bovine serum albumin modifications. Int J Biol Macromol. 2019;137:583\u201391.","journal-title":"Int J Biol Macromol"},{"key":"2923_CR242","first-page":"21","volume":"12","author":"M Ansari","year":"2020","unstructured":"Ansari M, Eslami H. Preparation and study of the inhibitory effect of nano-niosomes containing essential oil from artemisia absinthium on amyloid fibril formation. Studies. 2020;12:21\u20135.","journal-title":"Studies"},{"issue":"10","key":"2923_CR243","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.3390\/pharmaceutics14102252","volume":"14","author":"K Sun","year":"2022","unstructured":"Sun K, et al. Exosomes as CNS drug delivery tools and their applications. Pharmaceutics. 2022;14(10):2252.","journal-title":"Pharmaceutics"},{"issue":"6","key":"2923_CR244","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/biomedicines9060594","volume":"9","author":"Y-A Chen","year":"2021","unstructured":"Chen Y-A, et al. Mesenchymal stem cell-derived exosomes ameliorate Alzheimer\u2019s disease pathology and improve cognitive deficits. Biomedicines. 2021;9(6):594.","journal-title":"Biomedicines"},{"issue":"9","key":"2923_CR245","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.4103\/1673-5374.255978","volume":"14","author":"EE Reza-Zaldivar","year":"2019","unstructured":"Reza-Zaldivar EE, et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer\u2019s disease. Neural Regeneration Res. 2019;14(9):1626.","journal-title":"Neural Regeneration Res"},{"issue":"1","key":"2923_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-019-0150-2","volume":"16","author":"G-h Cui","year":"2019","unstructured":"Cui G-h, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer\u2019s disease. Immun Ageing. 2019;16(1):1\u201312.","journal-title":"Immun Ageing"},{"key":"2923_CR247","doi-asserted-by":"publisher","first-page":"113224","DOI":"10.1016\/j.biopha.2022.113224","volume":"152","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, et al. Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer\u2019s disease. Biomed Pharmacother. 2022;152:113224.","journal-title":"Biomed Pharmacother"},{"key":"2923_CR248","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fnins.2020.00564","volume":"14","author":"Y Jahangard","year":"2020","unstructured":"Jahangard Y, et al. Therapeutic effects of transplanted exosomes containing miR-29b to a rat model of Alzheimer\u2019s disease. Front NeuroSci. 2020;14:564.","journal-title":"Front NeuroSci"},{"key":"2923_CR249","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13346-021-00940-7","volume":"11","author":"LC Fonseca","year":"2021","unstructured":"Fonseca LC, et al. Intranasal drug delivery for treatment of Alzheimer\u2019s disease. Drug Delivery Translational Res. 2021;11:411\u201325.","journal-title":"Drug Delivery Translational Res"},{"issue":"2","key":"2923_CR250","first-page":"19","volume":"6","author":"R Arun Raj","year":"2019","unstructured":"Arun Raj R, Murali A. Formulation and evaluation of curcumin loaded transferosomal nasal in-situ gel for Alzheimer\u2019s disease. Res Rev AJ Drug Formul Dev Prod. 2019;6(2):19\u201331.","journal-title":"Res Rev AJ Drug Formul Dev Prod"},{"issue":"47","key":"2923_CR251","doi-asserted-by":"publisher","first-page":"43290","DOI":"10.1021\/acsomega.2c06215","volume":"7","author":"G Mishra","year":"2022","unstructured":"Mishra G, et al. Intranasally co-administered Berberine and Curcumin Loaded in Transfersomal vesicles Improved inhibition of amyloid formation and BACE-1. ACS Omega. 2022;7(47):43290\u2013305.","journal-title":"ACS Omega"},{"key":"2923_CR252","doi-asserted-by":"publisher","first-page":"113450","DOI":"10.1016\/j.biopha.2022.113450","volume":"153","author":"F Nojoki","year":"2022","unstructured":"Nojoki F, et al. Design and development of chitosan-insulin-transfersomes (transfersulin) as effective intranasal nanovesicles for the treatment of Alzheimer\u2019s disease: in vitro, in vivo, and ex vivo evaluations. Biomed Pharmacother. 2022;153:113450.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2923_CR253","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/17425247.2013.860130","volume":"11","author":"CC Mbah","year":"2014","unstructured":"Mbah CC, Builders PF, Attama AA. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus. Expert Opin Drug Deliv. 2014;11(1):45\u201359.","journal-title":"Expert Opin Drug Deliv"},{"key":"2923_CR254","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1208\/s12249-012-9767-6","volume":"13","author":"J Shi","year":"2012","unstructured":"Shi J, Wang Y, Luo G. Ligustrazine phosphate ethosomes for treatment of Alzheimer\u2019s disease, in vitro and in animal model studies. AAPS PharmSciTech. 2012;13:485\u201392.","journal-title":"AAPS PharmSciTech"},{"key":"2923_CR255","doi-asserted-by":"crossref","unstructured":"Barani M et al. Phytosomes as innovative delivery systems for phytochemicals: a comprehensive review of literature. Int J Nanomed. 2021;16:6983\u20137022.","DOI":"10.2147\/IJN.S318416"},{"key":"2923_CR256","doi-asserted-by":"crossref","unstructured":"Wattanathorn J et al. Memory-enhancing effect of a phytosome containing the combined extract of mulberry fruit and ginger in an animal model of ischemic stroke with metabolic syndrome. Oxidative Med Cell Longev. 2020;2020:3096826.","DOI":"10.1155\/2020\/3096826"},{"key":"2923_CR257","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fnins.2020.00170","volume":"14","author":"F Ullah","year":"2020","unstructured":"Ullah F, et al. Evaluation of phytosomal curcumin as an anti-inflammatory agent for chronic glial activation in the GFAP-IL6 mouse model. Front NeuroSci. 2020;14:170.","journal-title":"Front NeuroSci"},{"issue":"10","key":"2923_CR258","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/anie.201804067","volume":"58","author":"HM Barriga","year":"2019","unstructured":"Barriga HM, Holme MN, Stevens MM. Cubosomes: the next generation of smart lipid nanoparticles? Angew Chem Int Ed. 2019;58(10):2958\u201378.","journal-title":"Angew Chem Int Ed"},{"key":"2923_CR259","doi-asserted-by":"crossref","unstructured":"Elnaggar YS et al. Novel piperine-loaded tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer\u2019s disease: pharmaceutical, biological, and toxicological studies. Int J Nanomed. 2015;10:5459\u201373.","DOI":"10.2147\/IJN.S87336"},{"issue":"2","key":"2923_CR260","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejpb.2011.10.012","volume":"80","author":"H Wu","year":"2012","unstructured":"Wu H, et al. A novel small odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-\u03b225\u201335-treated rats following intranasal administration. Eur J Pharm Biopharm. 2012;80(2):368\u201378.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"2923_CR261","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"AA Yetisgin","year":"2020","unstructured":"Yetisgin AA, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.","journal-title":"Molecules"},{"key":"2923_CR262","doi-asserted-by":"crossref","unstructured":"Rout GK et al. Current advances in nanocarriers for biomedical research and their applications. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1053\u20131062.","DOI":"10.1080\/21691401.2018.1478843"},{"key":"2923_CR263","doi-asserted-by":"publisher","first-page":"111584","DOI":"10.1016\/j.colsurfb.2021.111584","volume":"200","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer\u2019s disease. Colloids Surf B. 2021;200:111584.","journal-title":"Colloids Surf B"},{"issue":"1","key":"2923_CR264","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):4790.","journal-title":"Nat Commun"},{"key":"2923_CR265","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s12035-019-01780-w","volume":"57","author":"N dos Santos Tramontin","year":"2020","unstructured":"dos Santos Tramontin N, et al. Gold nanoparticles treatment reverses brain damage in Alzheimer\u2019s disease model. Mol Neurobiol. 2020;57:926\u201336.","journal-title":"Mol Neurobiol"},{"issue":"7","key":"2923_CR266","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/pharmaceutics13071042","volume":"13","author":"A Cunha","year":"2021","unstructured":"Cunha A, et al. PLGA-based nanoparticles for neuroprotective drug delivery in neurodegenerative diseases. Pharmaceutics. 2021;13(7):1042.","journal-title":"Pharmaceutics"},{"key":"2923_CR267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"E S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E, et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization. J Nanobiotechnol. 2018;16:1\u201316.","journal-title":"J Nanobiotechnol"},{"key":"2923_CR268","doi-asserted-by":"publisher","unstructured":"Silva-Abreu M, Calpena AC, Andr\u00e9s-Benito P, Aso E, Romero IA, Roig-Carles D, et al. PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. Int J Nanomedicine. 2018;13:5577\u20135590. https:\/\/doi.org\/10.2147\/IJN.S171490.","DOI":"10.2147\/IJN.S171490"},{"key":"2923_CR269","doi-asserted-by":"crossref","unstructured":"Jeon SG et al. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer\u2019s disease-related pathology in 5XFAD mice. Nanomedicine. 2019;17:297\u2013307.","DOI":"10.1016\/j.nano.2019.02.004"},{"key":"2923_CR270","doi-asserted-by":"crossref","unstructured":"Xu R et al. Rhynchophylline loaded-mPEG-PLGA nanoparticles coated with Tween-80 for preliminary study in Alzheimer\u2019s disease. Int J Nanomed. 2020;15:1149\u201360.","DOI":"10.2147\/IJN.S236922"},{"key":"2923_CR271","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jtemb.2017.12.006","volume":"49","author":"A Vilella","year":"2018","unstructured":"Vilella A, et al. Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer\u2019s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J Trace Elem Med Biol. 2018;49:210\u201321.","journal-title":"J Trace Elem Med Biol"},{"issue":"3","key":"2923_CR272","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ibra.12126","volume":"9","author":"E Scarpa","year":"2023","unstructured":"Scarpa E, et al. Gold and silver nanoparticles in Alzheimer\u2019s and Parkinson\u2019s diagnostics and treatments. Ibrain. 2023;9(3):298\u2013315.","journal-title":"Ibrain"},{"key":"2923_CR273","doi-asserted-by":"publisher","first-page":"125288","DOI":"10.1016\/j.colsurfa.2020.125288","volume":"605","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li Y, Hu Y. Green synthesis of silver nanoparticles and their preventive effect in deficits in recognition and spatial memory in sporadic Alzheimer\u2019s rat model. Colloids Surf a. 2020;605:125288.","journal-title":"Colloids Surf a"},{"issue":"1","key":"2923_CR274","first-page":"3","volume":"1","author":"SP Ittiyavirah","year":"2015","unstructured":"Ittiyavirah SP, Ghosh R. Nootropic potential of silver nanoparticles of Boerhaavia diffusa and its ethanolic extract in high Fat Diet Model of Dementia in rats. Manipal J Pharm Sci. 2015;1(1):3.","journal-title":"Manipal J Pharm Sci"},{"key":"2923_CR275","first-page":"131","volume":"155","author":"H Ramshini","year":"2017","unstructured":"Ramshini H, et al. Silver nano particles ameliorate learning and spatial memory of male Wistar rats by prevention of amyloid fibril-induced neurotoxicity. Arch Ital Biol. 2017;155:131\u201341.","journal-title":"Arch Ital Biol"},{"issue":"3","key":"2923_CR276","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1038\/am.2013.88","volume":"6","author":"C Xu","year":"2014","unstructured":"Xu C, Qu X. Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014;6(3):e90\u201390.","journal-title":"NPG Asia Mater"},{"issue":"4","key":"2923_CR277","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/pharmaceutics14040756","volume":"14","author":"SM Danish","year":"2022","unstructured":"Danish SM, et al. Intranasal cerium oxide nanoparticles ameliorate cognitive function in rats with Alzheimer\u2019s via anti-oxidative pathway. Pharmaceutics. 2022;14(4):756.","journal-title":"Pharmaceutics"},{"key":"2923_CR278","doi-asserted-by":"crossref","unstructured":"Hu Y et al. Functionalized Cerium Dioxide nanoparticles with Antioxidative Neuroprotection for Alzheimer\u2019s Disease. Int J Nanomed. 2023;18:6797\u2013812.","DOI":"10.2147\/IJN.S434873"},{"key":"2923_CR279","doi-asserted-by":"publisher","first-page":"104755","DOI":"10.1016\/j.neuint.2020.104755","volume":"138","author":"T Wahle","year":"2020","unstructured":"Wahle T, et al. Evaluation of neurological effects of cerium dioxide nanoparticles doped with different amounts of zirconium following inhalation exposure in mouse models of Alzheimer\u2019s and vascular disease. Neurochem Int. 2020;138:104755.","journal-title":"Neurochem Int"},{"key":"2923_CR280","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.msec.2017.04.118","volume":"78","author":"N Akhtar","year":"2017","unstructured":"Akhtar N, et al. ZnO nanoflower based sensitive nano-biosensor for amyloid detection. Mater Sci Engineering: C. 2017;78:960\u20138.","journal-title":"Mater Sci Engineering: C"},{"key":"2923_CR281","doi-asserted-by":"crossref","unstructured":"Abdulmalek S et al. Protective effect of natural antioxidant, curcumin nanoparticles, and zinc oxide nanoparticles against type 2 diabetes-promoted hippocampal neurotoxicity in rats. Pharmaceutics. 2021;13(11):1937.","DOI":"10.3390\/pharmaceutics13111937"},{"key":"2923_CR282","doi-asserted-by":"publisher","unstructured":"Kesmati M, Sargholi Notarki Z, Issapareh N, Torabi M. Comparison the effect of zinc oxide and magnesium oxide nano particles on long term memory in adult male mice. Zahedan J Res Med Sci. 2016;18(9):e3473. https:\/\/doi.org\/10.17795\/zjrms-3473.","DOI":"10.17795\/zjrms-3473"},{"key":"2923_CR283","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jphotobiol.2018.11.008","volume":"190","author":"X Huo","year":"2019","unstructured":"Huo X, et al. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid \u03b2 aggregation in Alzheimer\u2019s disease. J Photochem Photobiol B. 2019;190:98\u2013102.","journal-title":"J Photochem Photobiol B"},{"key":"2923_CR284","doi-asserted-by":"publisher","first-page":"119246","DOI":"10.1016\/j.lfs.2021.119246","volume":"272","author":"B Gholamigeravand","year":"2021","unstructured":"Gholamigeravand B, et al. Synergistic effects of adipose-derived mesenchymal stem cells and selenium nanoparticles on streptozotocin-induced memory impairment in the rat. Life Sci. 2021;272:119246.","journal-title":"Life Sci"},{"key":"2923_CR285","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijbiomac.2020.03.079","volume":"154","author":"D Ji","year":"2020","unstructured":"Ji D, et al. Protective effects of chondroitin sulphate nano-selenium on a mouse model of Alzheimer\u2019s disease. Int J Biol Macromol. 2020;154:233\u201345.","journal-title":"Int J Biol Macromol"},{"key":"2923_CR286","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcis.2017.06.083","volume":"505","author":"D Sun","year":"2017","unstructured":"Sun D, et al. Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid \u03b2 aggregation for treating Alzheimer\u2019s disease. J Colloid Interface Sci. 2017;505:1001\u201310.","journal-title":"J Colloid Interface Sci"},{"key":"2923_CR287","doi-asserted-by":"publisher","first-page":"109960","DOI":"10.1016\/j.cbi.2022.109960","volume":"361","author":"J Kaur","year":"2022","unstructured":"Kaur J, et al. Advances in designing of polymeric micelles for biomedical application in brain related diseases. Chemico-Biol Interact. 2022;361:109960.","journal-title":"Chemico-Biol Interact"},{"key":"2923_CR288","first-page":"80","volume":"1","author":"S Hagl","year":"2014","unstructured":"Hagl S, et al. Curcumin micelles improve mitochondrial function in a mouse model of Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2014;1:80\u20133.","journal-title":"J Prev Alzheimers Dis"},{"key":"2923_CR289","doi-asserted-by":"publisher","first-page":"119844","DOI":"10.1016\/j.biomaterials.2020.119844","volume":"238","author":"P Yang","year":"2020","unstructured":"Yang P, et al. Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer\u2019s disease. Biomaterials. 2020;238:119844.","journal-title":"Biomaterials"},{"issue":"6","key":"2923_CR290","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1039\/C5NJ00309A","volume":"39","author":"T Wasiak","year":"2015","unstructured":"Wasiak T, et al. Cationic phosphorus dendrimers and therapy for Alzheimer\u2019s disease. New J Chem. 2015;39(6):4852\u20139.","journal-title":"New J Chem"},{"issue":"8","key":"2923_CR291","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1021\/acschemneuro.9b00286","volume":"10","author":"A Gothwal","year":"2019","unstructured":"Gothwal A, et al. Behavioral and biochemical implications of dendrimeric rivastigmine in memory-deficit and Alzheimer\u2019s induced rodents. ACS Chem Neurosci. 2019;10(8):3789\u201395.","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"2923_CR292","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1021\/acs.bioconjchem.9b00505","volume":"30","author":"A Gothwal","year":"2019","unstructured":"Gothwal A, et al. Lactoferrin coupled lower generation PAMAM dendrimers for brain targeted delivery of memantine in aluminum-chloride-induced Alzheimer\u2019s disease in mice. Bioconjug Chem. 2019;30(10):2573\u201383.","journal-title":"Bioconjug Chem"},{"issue":"10","key":"2923_CR293","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1021\/bm400948z","volume":"14","author":"O Klementieva","year":"2013","unstructured":"Klementieva O, et al. Effect of poly (propylene imine) glycodendrimers on \u03b2-amyloid aggregation in vitro and in APP\/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer\u2019s disease. Biomacromolecules. 2013;14(10):3570\u201380.","journal-title":"Biomacromolecules"},{"issue":"5","key":"2923_CR294","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","volume":"37","author":"A Kaur","year":"2020","unstructured":"Kaur A, et al. Memantine nanoemulsion: a new approach to treat Alzheimer\u2019s disease. J Microencapsul. 2020;37(5):355\u201365.","journal-title":"J Microencapsul"},{"key":"2923_CR295","doi-asserted-by":"crossref","unstructured":"Song Y et al. Osthole-loaded nanoemulsion enhances brain target in the treatment of Alzheimer\u2019s disease via intranasal administration. Oxidative Med Cell Longev. 2021;2021:8844455.","DOI":"10.1155\/2021\/8844455"},{"key":"2923_CR296","doi-asserted-by":"crossref","unstructured":"Alaqeel NK, AlSheikh MH, Al-Hariri MT. Quercetin nanoemulsion ameliorates neuronal dysfunction in experimental Alzheimer\u2019s disease model. Antioxidants. 2022;11(10):1986.","DOI":"10.3390\/antiox11101986"},{"key":"2923_CR297","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.biopha.2017.08.074","volume":"95","author":"N Ismail","year":"2017","unstructured":"Ismail N, et al. Thymoquinone-rich fraction nanoemulsion (TQRFNE) decreases A\u03b240 and A\u03b242 levels by modulating APP processing, up-regulating IDE and LRP1, and down-regulating BACE1 and RAGE in response to high fat\/cholesterol diet-induced rats. Biomed Pharmacother. 2017;95:780\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2923_CR298","first-page":"9","volume":"1","author":"SS Beniwal","year":"2023","unstructured":"Beniwal SS, et al. Evaluation of the neuroprotective activity of citral nanoemulsion on Alzheimer\u2019s disease-type dementia in a preclinical model: the assessment of cognitive and neurobiochemical responses. Life. 2023;1(1):9\u201317.","journal-title":"Life"},{"issue":"3","key":"2923_CR299","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3233\/JAD-190083","volume":"69","author":"S Sadegh Malvajerd","year":"2019","unstructured":"Sadegh Malvajerd S, et al. Neuroprotective potential of curcumin-loaded nanostructured lipid carrier in an animal model of Alzheimer\u2019s disease: behavioral and biochemical evidence. J Alzheimers Dis. 2019;69(3):671\u201386.","journal-title":"J Alzheimers Dis"},{"key":"2923_CR300","doi-asserted-by":"crossref","unstructured":"Shehata MK, Ismail AA, Kamel MA. Combined donepezil with astaxanthin via nanostructured lipid carriers effective delivery to brain for Alzheimer\u2019s disease in rat model. Int J Nanomed. 2023;18:4193\u2013227.","DOI":"10.2147\/IJN.S417928"},{"key":"2923_CR301","doi-asserted-by":"publisher","unstructured":"Shehata MK, Ismail AA, Kamel MA. Nose to brain delivery of astaxanthin-loaded nanostructured lipid carriers in rat model of alzheimer's disease: preparation, in vitro and in vivo evaluation. Int J Nanomedicine. 2023;18:1631-1658. https:\/\/doi.org\/10.2147\/IJN.S402447.","DOI":"10.2147\/IJN.S402447"},{"key":"2923_CR302","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jddst.2018.11.021","volume":"49","author":"A Anand","year":"2019","unstructured":"Anand A, et al. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. Elegans model. J Drug Deliv Sci Technol. 2019;49:219\u201326.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"2923_CR303","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5958\/0975-4377.2016.00011.2","volume":"8","author":"P Salve","year":"2016","unstructured":"Salve P, Pise S, Bali N. Formulation and evaluation of solid lipid nanoparticle based Transdermal Drug Delivery System for Alzheimer\u2019s Disease. Res J Pharm Dosage Forms Technol. 2016;8(2):73\u201380.","journal-title":"Res J Pharm Dosage Forms Technol"},{"issue":"1","key":"2923_CR304","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/pharmaceutics15010221","volume":"15","author":"MG Shivananjegowda","year":"2023","unstructured":"Shivananjegowda MG, et al. Development and evaluation of solid lipid nanoparticles for the clearance of A\u03b2 in Alzheimer\u2019s disease. Pharmaceutics. 2023;15(1):221.","journal-title":"Pharmaceutics"},{"key":"2923_CR305","doi-asserted-by":"publisher","first-page":"111838","DOI":"10.1016\/j.colsurfb.2021.111838","volume":"205","author":"S Saini","year":"2021","unstructured":"Saini S, et al. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: a preclinical evidence. Colloids Surf B. 2021;205:111838.","journal-title":"Colloids Surf B"},{"key":"2923_CR306","doi-asserted-by":"publisher","first-page":"107082","DOI":"10.1016\/j.nlm.2019.107082","volume":"166","author":"T Dara","year":"2019","unstructured":"Dara T, et al. Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166:107082.","journal-title":"Neurobiol Learn Mem"},{"issue":"10","key":"2923_CR307","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3390\/antiox11101863","volume":"11","author":"A Campisi","year":"2022","unstructured":"Campisi A, et al. Effect of unloaded and curcumin-loaded solid lipid nanoparticles on tissue transglutaminase isoforms expression levels in an experimental model of Alzheimer\u2019s disease. Antioxidants. 2022;11(10):1863.","journal-title":"Antioxidants"},{"issue":"1","key":"2923_CR308","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1039\/C6CS00517A","volume":"46","author":"S Kumar","year":"2017","unstructured":"Kumar S, et al. Carbon nanotubes: a novel material for multifaceted applications in human healthcare. Chem Soc Rev. 2017;46(1):158\u201396.","journal-title":"Chem Soc Rev"},{"key":"2923_CR309","first-page":"427","volume-title":"Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease","author":"Z Yang","year":"2010","unstructured":"Yang Z, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Volume 6. Nanomedicine: Nanotechnology, Biology and Medicine; 2010. pp. 427\u201341. 3."},{"issue":"9","key":"2923_CR310","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1021\/nl501839q","volume":"14","author":"X Xue","year":"2014","unstructured":"Xue X, et al. Single-walled carbon nanotubes alleviate autophagic\/lysosomal defects in primary glia from a mouse model of Alzheimer\u2019s disease. Nano Lett. 2014;14(9):5110\u20137.","journal-title":"Nano Lett"},{"issue":"11","key":"2923_CR311","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/bios12111059","volume":"12","author":"P Ranjan","year":"2022","unstructured":"Ranjan P, Khan R. Electrochemical Immunosensor for early detection of \u03b2-amyloid alzheimer\u2019s disease biomarker based on aligned carbon nanotubes gold nanocomposites. Biosensors. 2022;12(11):1059.","journal-title":"Biosensors"},{"issue":"9","key":"2923_CR312","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3390\/molecules27092902","volume":"27","author":"T-C Ho","year":"2022","unstructured":"Ho T-C, et al. Hydrogels: Properties and applications in biomedicine. Molecules. 2022;27(9):2902.","journal-title":"Molecules"},{"key":"2923_CR313","doi-asserted-by":"crossref","unstructured":"Ribeiro TdC et al. Curcumin-loaded mesoporous silica nanoparticles dispersed in thermo-responsive hydrogel as potential Alzheimer disease therapy. Pharmaceutics. 2022;14(9):1976.","DOI":"10.3390\/pharmaceutics14091976"},{"issue":"1","key":"2923_CR314","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jtcms.2021.01.002","volume":"8","author":"G Ou","year":"2021","unstructured":"Ou G, et al. Preventive effect of nasal timosaponin BII-loaded temperature-\/ion-sensitive in situ hydrogels on Alzheimer\u2019s disease. J Traditional Chin Med Sci. 2021;8(1):59\u201364.","journal-title":"J Traditional Chin Med Sci"},{"key":"2923_CR315","doi-asserted-by":"publisher","first-page":"119115","DOI":"10.1016\/j.ijpharm.2020.119115","volume":"578","author":"W Chen","year":"2020","unstructured":"Chen W, et al. Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of Alzheimer\u2019s disease induced by lipopolysaccharides. Int J Pharm. 2020;578:119115.","journal-title":"Int J Pharm"},{"key":"2923_CR316","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.crphar.2022.100100","volume":"3","author":"M Rajkumar","year":"2022","unstructured":"Rajkumar M, et al. Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer\u2019s disease in Wistar rats. Curr Res Pharmacol Drug Discovery. 2022;3:100100.","journal-title":"Curr Res Pharmacol Drug Discovery"},{"issue":"6","key":"2923_CR317","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.4103\/1673-5374.327328","volume":"17","author":"C Hernandez","year":"2022","unstructured":"Hernandez C, Shukla S. Liposome based drug delivery as a potential treatment option for Alzheimer\u2019s disease. Neural Regeneration Res. 2022;17(6):1190\u20138.","journal-title":"Neural Regeneration Res"},{"issue":"4","key":"2923_CR318","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/15701638113109990031","volume":"10","author":"N Ravouru","year":"2013","unstructured":"Ravouru N, Kondreddy P, Korakanchi D. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol. 2013;10(4):270\u201382.","journal-title":"Curr Drug Discov Technol"},{"key":"2923_CR319","doi-asserted-by":"publisher","first-page":"104974","DOI":"10.1016\/j.neubiorev.2022.104974","volume":"144","author":"R Kandimalla","year":"2023","unstructured":"Kandimalla R, et al. Exosome-based approaches in the management of Alzheimer\u2019s disease. Neurosci Biobehavioral Reviews. 2023;144:104974.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"2923_CR320","doi-asserted-by":"publisher","first-page":"103087","DOI":"10.1016\/j.jddst.2021.103087","volume":"69","author":"SS Rajamma","year":"2022","unstructured":"Rajamma SS, et al. Geophila repens phytosome-loaded intranasal gel with improved nasal permeation for the effective treatment of Alzheimer\u2019s disease. J Drug Deliv Sci Technol. 2022;69:103087.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2\u20133","key":"2923_CR321","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jconrel.2005.07.024","volume":"108","author":"C Roney","year":"2005","unstructured":"Roney C, et al. Targeted nanoparticles for drug delivery through the blood\u2013brain barrier for Alzheimer\u2019s disease. J Controlled Release. 2005;108(2\u20133):193\u2013214.","journal-title":"J Controlled Release"},{"key":"2923_CR322","doi-asserted-by":"publisher","unstructured":"Sivanesan S, Rajeshkumar S. Gold nanoparticles in diagnosis and treatment of alzheimer\u2019s disease. In: Rai M, Yadav A,\u00a0editors. Nanobiotechnology in neurodegenerative diseases. Springer, Cham; 2019. https:\/\/doi.org\/10.1007\/978-3-030-30930-5_12","DOI":"10.1007\/978-3-030-30930-5_12"},{"issue":"5","key":"2923_CR323","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1007\/s13204-022-02638-9","volume":"13","author":"H Zeng","year":"2023","unstructured":"Zeng H, et al. The impacts of curcumin on learning memory function in Alzheimer\u2019s disease under the poly lactic-co-glycolic acid nanoparticle drug carrier. Appl Nanosci. 2023;13(5):3483\u201391.","journal-title":"Appl Nanosci"},{"issue":"29","key":"2923_CR324","doi-asserted-by":"publisher","first-page":"18009","DOI":"10.1039\/D1RA01725J","volume":"11","author":"SS El-Hawwary","year":"2021","unstructured":"El-Hawwary SS, et al. Green-synthesized zinc oxide nanoparticles, anti-alzheimer potential and the metabolic profiling of Sabal Blackburniana grown in Egypt supported by molecular modelling. RSC Adv. 2021;11(29):18009\u201325.","journal-title":"RSC Adv"},{"key":"2923_CR325","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.biomaterials.2018.12.027","volume":"197","author":"J Sun","year":"2019","unstructured":"Sun J, et al. Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of Alzheimer\u2019s disease. Biomaterials. 2019;197:417\u201331.","journal-title":"Biomaterials"},{"issue":"4","key":"2923_CR326","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/pharmaceutics14040835","volume":"14","author":"P Poudel","year":"2022","unstructured":"Poudel P, Park S. Recent advances in the treatment of Alzheimer\u2019s disease using nanoparticle-based drug delivery systems. Pharmaceutics. 2022;14(4):835.","journal-title":"Pharmaceutics"},{"issue":"08","key":"2923_CR327","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/a-1886-3208","volume":"72","author":"A Singh","year":"2022","unstructured":"Singh A, et al. Dendrimers: a neuroprotective lead in alzheimer disease: a review on its synthetic approach and applications. Drug Res. 2022;72(08):417\u201323.","journal-title":"Drug Res"},{"key":"2923_CR328","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s13346-020-00754-z","volume":"10","author":"A Kaur","year":"2020","unstructured":"Kaur A, et al. Treatment of Alzheimer\u2019s diseases using donepezil nanoemulsion: an intranasal approach. Drug Delivery Translational Res. 2020;10:1862\u201375.","journal-title":"Drug Delivery Translational Res"},{"key":"2923_CR329","doi-asserted-by":"crossref","unstructured":"Cunha S et al. Improving drug delivery for Alzheimer\u2019s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int J Nanomed. 2021;16:4373\u201390.","DOI":"10.2147\/IJN.S305851"},{"key":"2923_CR330","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.phrs.2019.03.023","volume":"143","author":"M Mohajeri","year":"2019","unstructured":"Mohajeri M, et al. Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer\u2019s disease? Pharmacol Res. 2019;143:186\u2013203.","journal-title":"Pharmacol Res"},{"issue":"11","key":"2923_CR331","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/pharmaceutics14112296","volume":"14","author":"D Nunes","year":"2022","unstructured":"Nunes D, Loureiro JA, Pereira MC. Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer\u2019s drugs. Pharmaceutics. 2022;14(11):2296.","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"2923_CR332","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijpharm.2017.07.080","volume":"530","author":"S Lohan","year":"2017","unstructured":"Lohan S, et al. Anti-alzheimer\u2019s potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int J Pharm. 2017;530(1\u20132):263\u201378.","journal-title":"Int J Pharm"},{"issue":"2","key":"2923_CR333","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/mabi.201500268","volume":"16","author":"SA Sorokina","year":"2016","unstructured":"Sorokina SA, et al. Disruption of amyloid prion protein aggregates by cationic pyridylphenylene dendrimers. Macromol Biosci. 2016;16(2):266\u201375.","journal-title":"Macromol Biosci"},{"key":"2923_CR334","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1007\/s12035-016-0136-4","volume":"54","author":"T Ali","year":"2017","unstructured":"Ali T, et al. Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in an A\u03b2 1\u201342 mouse model of Alzheimer\u2019s disease. Mol Neurobiol. 2017;54:6490\u2013506.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"2923_CR335","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.nano.2017.02.013","volume":"13","author":"J Ruff","year":"2017","unstructured":"Ruff J, et al. The effects of gold nanoparticles functionalized with \u00df-amyloid specific peptides on an in vitro model of blood\u2013brain barrier. Nanomed Nanotechnol Biol Med. 2017;13(5):1645\u201352.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"2923_CR336","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuint.2017.02.012","volume":"108","author":"E Conti","year":"2017","unstructured":"Conti E, et al. Multifunctional liposomes interact with Abeta in human biological fluids: therapeutic implications for Alzheimer\u2019s disease. Neurochem Int. 2017;108:60\u20135.","journal-title":"Neurochem Int"},{"key":"2923_CR337","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","volume":"145","author":"JA Loureiro","year":"2016","unstructured":"Loureiro JA, et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer\u2019s disease treatment. Colloids Surf B. 2016;145:8\u201313.","journal-title":"Colloids Surf B"},{"key":"2923_CR338","doi-asserted-by":"crossref","unstructured":"Kuo Y-C et al. Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer\u2019s disease treatment. Int J Nanomed. 2017;12:1757\u201374.","DOI":"10.2147\/IJN.S128396"},{"issue":"4","key":"2923_CR339","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/03639045.2016.1275668","volume":"43","author":"M Karimzadeh","year":"2017","unstructured":"Karimzadeh M, Rashidi L, Ganji F. Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm. 2017;43(4):628\u201336.","journal-title":"Drug Dev Ind Pharm"},{"key":"2923_CR340","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.actbio.2016.09.010","volume":"46","author":"L Yang","year":"2016","unstructured":"Yang L, et al. Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer\u2019s disease treatment. Acta Biomater. 2016;46:177\u201390.","journal-title":"Acta Biomater"},{"key":"2923_CR341","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.msec.2015.10.026","volume":"59","author":"S Mirsadeghi","year":"2016","unstructured":"Mirsadeghi S, et al. Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid beta fibrillation process. Mater Sci Engineering: C. 2016;59:390\u20137.","journal-title":"Mater Sci Engineering: C"},{"key":"2923_CR342","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","volume":"80","author":"Y Liu","year":"2016","unstructured":"Liu Y, et al. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer\u2019s disease mice. Biomaterials. 2016;80:33\u201345.","journal-title":"Biomaterials"},{"issue":"10","key":"2923_CR343","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/jps.24557","volume":"104","author":"YS Elnaggar","year":"2015","unstructured":"Elnaggar YS, et al. Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci. 2015;104(10):3544\u201356.","journal-title":"J Pharm Sci"},{"key":"2923_CR344","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jcis.2017.06.093","volume":"505","author":"H Liu","year":"2017","unstructured":"Liu H, et al. Iminodiacetic acid-conjugated nanoparticles as a bifunctional modulator against Zn2+-mediated amyloid \u03b2-protein aggregation and cytotoxicity. J Colloid Interface Sci. 2017;505:973\u201382.","journal-title":"J Colloid Interface Sci"},{"key":"2923_CR345","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcis.2016.12.038","volume":"491","author":"H Liu","year":"2017","unstructured":"Liu H, et al. Synergistic effects of negatively charged hydrophobic nanoparticles and (\u2013)-epigallocatechin-3-gallate on inhibiting amyloid \u03b2-protein aggregation. J Colloid Interface Sci. 2017;491:305\u201312.","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"2923_CR346","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","volume":"10","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, et al. Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer\u2019s disease. ACS Nano. 2016;10(2):2860\u201370.","journal-title":"ACS Nano"},{"key":"2923_CR347","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","volume":"152","author":"G Rassu","year":"2017","unstructured":"Rassu G, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy. Colloids Surf B. 2017;152:296\u2013301.","journal-title":"Colloids Surf B"},{"issue":"2","key":"2923_CR348","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/molecules22020277","volume":"22","author":"JA Loureiro","year":"2017","unstructured":"Loureiro JA, et al. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer\u2019s disease. Molecules. 2017;22(2):277.","journal-title":"Molecules"},{"issue":"4","key":"2923_CR349","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"S Misra","year":"2016","unstructured":"Misra S, et al. Galantamine-loaded solid\u2013lipid nanoparticles for enhanced brain delivery: Preparation, characterization, in vitro and in vivo evaluations. Drug Delivery. 2016;23(4):1434\u201343.","journal-title":"Drug Delivery"},{"key":"2923_CR350","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.msec.2017.03.303","volume":"77","author":"Y-C Kuo","year":"2017","unstructured":"Kuo Y-C, Rajesh R. Nerve growth factor-loaded heparinized cationic solid lipid nanoparticles for regulating membrane charge of induced pluripotent stem cells during differentiation. Mater Sci Engineering: C. 2017;77:680\u20139.","journal-title":"Mater Sci Engineering: C"},{"issue":"5","key":"2923_CR351","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/nano6050087","volume":"6","author":"A Polchi","year":"2016","unstructured":"Polchi A, et al. Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: formulation and in vitro characterization. Nanomaterials. 2016;6(5):87.","journal-title":"Nanomaterials"},{"issue":"6","key":"2923_CR352","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"7","key":"2923_CR353","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archneurol.2012.85","volume":"69","author":"DR Galasko","year":"2012","unstructured":"Galasko DR, et al. Antioxidants for Alzheimer Disease: a Randomized Clinical Trial with Cerebrospinal Fluid Biomarker measures. Arch Neurol. 2012;69(7):836\u201341.","journal-title":"Arch Neurol"},{"issue":"11","key":"2923_CR354","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, et al. Targeting Prodromal Alzheimer Disease with Avagacestat: a Randomized Clinical Trial. JAMA Neurol. 2015;72(11):1324\u201333.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2923_CR355","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archneurol.2010.229","volume":"68","author":"DS Geldmacher","year":"2011","unstructured":"Geldmacher DS, et al. A Randomized Pilot Clinical Trial of the safety of Pioglitazone in treatment of patients with Alzheimer Disease. Arch Neurol. 2011;68(1):45\u201350.","journal-title":"Arch Neurol"},{"issue":"7","key":"2923_CR356","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, et al. Effect of Citalopram on Agitation in Alzheimer Disease: the CitAD Randomized Clinical Trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA"},{"issue":"10","key":"2923_CR357","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","volume":"76","author":"CH van Dyck","year":"2019","unstructured":"van Dyck CH, et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer Disease: a Randomized Clinical Trial. JAMA Neurol. 2019;76(10):1219\u201329.","journal-title":"JAMA Neurol"},{"issue":"17","key":"2923_CR358","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","volume":"82","author":"D Galasko","year":"2014","unstructured":"Galasko D, et al. Clinical trial of an inhibitor of RAGE-A\u03b2 interactions in Alzheimer disease. Neurology. 2014;82(17):1536\u201342.","journal-title":"Neurology"},{"issue":"8","key":"2923_CR359","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","volume":"43","author":"J Rogers","year":"1993","unstructured":"Rogers J, et al. Clinical trial of indomethacin in Alzheimer\u2019s disease. Neurology. 1993;43(8):1609\u20131609.","journal-title":"Neurology"},{"issue":"5","key":"2923_CR360","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"MH Tuszynski","year":"2005","unstructured":"Tuszynski MH, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551\u20135.","journal-title":"Nat Med"},{"issue":"1","key":"2923_CR361","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic mild cognitive impairment: a Pilot Clinical Trial. Arch Neurol. 2012;69(1):29\u201338.","journal-title":"Arch Neurol"},{"key":"2923_CR362","doi-asserted-by":"crossref","unstructured":"Sperling R et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A truncated randomized phase 2b\/3 clinical trial. JAMA Neurology. 2021;78(3):293\u2013301.","DOI":"10.1001\/jamaneurol.2020.4857"},{"issue":"2","key":"2923_CR363","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"A Atri","year":"2018","unstructured":"Atri A, et al. Effect of Idalopirdine as Adjunct to Cholinesterase inhibitors on change in cognition in patients with Alzheimer Disease: three randomized clinical trials. JAMA. 2018;319(2):130\u201342.","journal-title":"JAMA"},{"issue":"3","key":"2923_CR364","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","volume":"14","author":"J Mintzer","year":"2006","unstructured":"Mintzer J, et al. Risperidone in the treatment of psychosis of Alzheimer Disease: results from a prospective clinical trial. Am J Geriatric Psychiatry. 2006;14(3):280\u201391.","journal-title":"Am J Geriatric Psychiatry"},{"key":"2923_CR365","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05686044?cond=alzheimer&aggFilters=status:act&rank=2 (Accessed 20 Dec 2023)."},{"key":"2923_CR366","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05696483?cond=alzheimer&aggFilters=status:act&rank=6 (Accessed 20 Dec 2023)."},{"key":"2923_CR367","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05181475?cond=alzheimer&aggFilters=status:act&rank=10 (Accessed 20 Dec 2023)."},{"key":"2923_CR368","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05063539?cond=alzheimer&aggFilters=status:act&page=2&rank=12 (Accessed 20 Dec 2023)."},{"key":"2923_CR369","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05058040?cond=alzheimer&aggFilters=status:act&page=2&rank=13 (Accessed 20 Dec 2023)."},{"key":"2923_CR370","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05026177?cond=alzheimer&aggFilters=status:act&page=2&rank=14 (Accessed 20 Dec 2023)."},{"key":"2923_CR371","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04994483?cond=alzheimer&aggFilters=status:act&page=2&rank=15 (Accessed 20 Dec 2023)."},{"key":"2923_CR372","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04592874?cond=alzheimer&aggFilters=status:act&page=2&rank=19 (Accessed 20 Dec 2023)."},{"key":"2923_CR373","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04437511?cond=alzheimer&aggFilters=status:act&page=2&rank=20 (Accessed 20 Dec 2023)."},{"key":"2923_CR374","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04388254?cond=alzheimer&aggFilters=status:act&page=3&rank=21 (Accessed 20 Dec 2023)."},{"key":"2923_CR375","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04381468?cond=alzheimer&aggFilters=status:act&page=3&rank=22 (Accessed 22 Dec 2023)."},{"key":"2923_CR376","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03821857?cond=alzheimer&aggFilters=status:act&page=3&rank=27 (Accessed 22 Dec 2023)."},{"key":"2923_CR377","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03748303?cond=alzheimer&aggFilters=status:act&page=3&rank=30 (Accessed 22 Dec 2023)."},{"key":"2923_CR378","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03402503?cond=alzheimer&aggFilters=status:act&page=4&rank=31 (Accessed 22 Dec 2023)."},{"key":"2923_CR379","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04451408?cond=alzheimer&aggFilters=status:act&page=4&rank=40 (Accessed 22 Dec 2023)."},{"key":"2923_CR380","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05015374?cond=alzheimer&aggFilters=status:act&page=5&rank=41 (Accessed 22 Dec 2023)."},{"key":"2923_CR381","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06019117?cond=alzheimer&aggFilters=status:act&page=5&rank=42 (Accessed 22 Dec 2023)."},{"key":"2923_CR382","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04777409?cond=alzheimer&aggFilters=status:act&page=5&rank=43 (Accessed 23 Dec 2023)."},{"key":"2923_CR383","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04552795?cond=alzheimer&aggFilters=status:act&page=5&rank=48 (Accessed 23 Dec 2023)."},{"key":"2923_CR384","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04795466?cond=alzheimer&aggFilters=status:act&page=6&rank=53 (Accessed 23 Dec 2023)."},{"key":"2923_CR385","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04619420?cond=alzheimer&aggFilters=status:act&page=6&rank=57 (Accessed 23 Dec 2023)."},{"key":"2923_CR386","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04200911?cond=alzheimer&aggFilters=status:act&page=6&rank=58 (Accessed 23 Dec 2023)."},{"key":"2923_CR387","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05328115?cond=alzheimer&aggFilters=status:act&page=7&rank=64 (Accessed 23 Dec 2023)."},{"key":"2923_CR388","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03185208?cond=alzheimer&aggFilters=status:act&page=8&rank=74 (Accessed 23 Dec 2023)."},{"key":"2923_CR389","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03282916?cond=alzheimer&aggFilters=status:act&page=8&rank=78 (Accessed 23 Dec 2023)."},{"key":"2923_CR390","unstructured":"https:\/\/patents.google.com\/patent\/US20190338363A1\/en?q=(Alzheimer)&oq=Alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR391","unstructured":"https:\/\/patents.google.com\/patent\/AU2009202023B2\/en?q=(alzheimer)&oq=alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR392","unstructured":"https:\/\/patents.google.com\/patent\/US7640062B2\/en?q=(alzheimer)&oq=alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR393","unstructured":"https:\/\/patents.google.com\/patent\/JP7182316B2\/en?q=(Alzheimer)&oq=Alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR394","unstructured":"https:\/\/patents.google.com\/patent\/EP2086538B1\/en?q=(Alzheimer)&oq=Alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR395","unstructured":"https:\/\/patents.google.com\/patent\/US8921321B2\/en?q=(Alzheimer)&oq=Alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR396","unstructured":"https:\/\/patents.google.com\/patent\/JP6784646B2\/en?q=(Alzheimer)&oq=Alzheimer (Accessed 27 Dec 2023)."},{"key":"2923_CR397","unstructured":"https:\/\/patents.google.com\/patent\/JP7210620B2\/en?q=(Alzheimer)&oq=Alzheimer&page=1 (Accessed 29 Dec 2023)."},{"key":"2923_CR398","unstructured":"https:\/\/patents.google.com\/patent\/AU2019202459B2\/en?q=(Alzheimer)&oq=Alzheimer&page=1. Accessed 29 Dec 2023."},{"key":"2923_CR399","unstructured":"https:\/\/patents.google.com\/patent\/JP6864763B2\/en?q=(Alzheimer)&oq=Alzheimer&page=1 (Accessed 29 Dec 2023)."},{"key":"2923_CR400","unstructured":"https:\/\/patents.google.com\/patent\/US9248104B2\/en?q=(Alzheimer)&oq=Alzheimer&page=2 (Accessed 29 Dec 2023)."},{"key":"2923_CR401","unstructured":"https:\/\/patents.google.com\/patent\/CA2722314C\/en?q=(Alzheimer)&oq=Alzheimer&page=2 (Accessed 29 Dec 2023)."},{"key":"2923_CR402","unstructured":"https:\/\/patents.google.com\/patent\/US20220406435A1\/en?q=(Alzheimer)&oq=Alzheimer&page=2 (Accessed 30 Dec 2023)."},{"key":"2923_CR403","unstructured":"https:\/\/patents.google.com\/patent\/CN103842362B\/en?q=(Alzheimer)&oq=Alzheimer&page=2 (Accessed 30 Dec 2023)."},{"key":"2923_CR404","unstructured":"https:\/\/patents.google.com\/patent\/EP2001503B1\/en?q=(Alzheimer)&oq=Alzheimer&page=2 (Accessed 30 Dec 2023)."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02923-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-02923-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02923-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T04:42:10Z","timestamp":1729744930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-02923-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":404,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-02923-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"207"}}